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1. Epidemiology 
 
Definition 
 
An exacerbation of COPD is defined as an acute event characterized by a worsening of the patient’s 
respiratory symptoms that is beyond normal day-to-day variations and leads to a change in 
medication 1. 
Exacerbations of COPD have been defined as symptom-based or symptoms plus event based 2. 
Anthonisen et al graded exacerbations, based on the three cardinal symptoms during an 
exacerbation: increased dyspnea, sputum purulence and sputum volume 3. The Anthonisen 
classification consists of three types: type 1 (all three cardinal symptoms), type 2 (two cardinal 
symptoms) and type 3 (one cardinal symptom plus one of the following: an upper respiratory tract 
infection in the past 5 days, fever without other cause, increased wheezing or cough, or an increase 
in heart rate or respiratory rate by 20% compared with baseline readings). However, a standardized 
symptom-based definition is likely to be complicated by the highly varied nature of COPD 
symptomatology during exacerbations. 
Classification of exacerbations based on events offers a simple approach and is therefore widely used 
in clinical trials. A distinction is made between mild (increased use of rescue bronchodilators), 
moderate (use of either oral antibiotics and/or corticosteroids) and severe exacerbations 
(hospitalizations) 4. 
A disadvantage of the event-based classification is the underreporting of exacerbations, since only 
50% of exacerbations according to Anthonisen criteria are reported to the physician 5, 6. 
 
Prevalence 
 
COPD is a leading cause of morbidity and mortality and the prevalence is expected to increase in the 
coming decades 7, 8. The latter is caused by an aging population 9 in combination with continued 
exposure to COPD risk factors, such as tobacco smoke 8 and air pollution from indoor cooking 10. 
There is a large variation in exacerbation-rate between patients 11.  
Worsening airflow limitation is associated with an increasing prevalence of exacerbations and risk of 
death 12-14. The average exacerbation rate climbs from 0.7-0.9 per year in GOLD 2 (moderate airflow 
obstruction) to 1.2-2.0 per year in GOLD 4 (very severe) 12-14. 
However, the best predictor of frequent exacerbations is a history of previous frequent events (two 
or more exacerbations per year) 14. 
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2.   Pathophysiology 
 
Increased airway inflammation is probably the primary event of COPD exacerbations and may be 
caused by bacterial and viral infections, environmental pollutants and cigarette smoke 15. The 
inflammation leads to bronchospasm, mucosal edema and sputum impaction, which results in 
increased airways resistance 15. 
The main pathophysiological mechanism during a severe exacerbation of COPD is critical airflow 
limitation with lung hyperinflation, which leads to serious mechanical consequences 16, 17. Worsening 
of VA/Q abnormalities can result in hypoxemia 18. 
 
3. Aetiology 
 
Exacerbations of COPD are triggered by infection with bacteria or viruses, environmental pollutants, 
or unknown factors 19. 
More than 50% of COPD exacerbations are caused by viral and bacterial infections 19-22. 
In case of bacterial infections Haemophilus influenzae is the most frequently isolated microorganism 
(20-30%), followed by Streptococcus pneumoniae (10-15%), Moraxella catarrhalis (10-15%) and 
Pseudomonas aeruginosa (5-10%) 23. 
Viral infections also play an important role, both alone and in combination with bacteria and account 
for approximately 30% of exacerbations 24, 25. Recent polymerase chain reaction (PCR) or reverse 
transcription (RT)-PCR based studies suggest an even higher prevalence of viral infections during 
exacerbations (22-64%) 26, 27. Rhinovirus, influenza virus and respiratory syncitial virus are most 
frequently isolated 25. 
By inducing impairment of antibacterial host defence, viral infections frequently precipitate bacterial 
infections in COPD patients 28, 29.  
Sethi et al developed the concept of the acquisition of a new bacterial strain as the main cause of a 
bacterial infection 30. It was found that the frequency of exacerbations increased more than two-fold 
when a new strain of a pathogen was isolated from sputum 30. 
In a recent study by Bafadhel et al four distinct biologic exacerbation clusters were identified that 
were clinically indistinguishable 31. These clusters, bacterial-, viral-, eosinophilic predominant and 
pauciinflammatory, may identify patients that appropriately require corticosteroids and antibiotics at 
the onset of an exacerbation. It appeared that the phenotype of the exacerbation remained constant 
in a given patient 31. 
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4. Characteristics of COPD exacerbations 
 
Exacerbation frequency 
 
It has been shown that exacerbation frequency increases with disease severity, using a symptom-
based definition 32, 33. 
In the Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study, 
a large 3-year observational multi-centre international study aimed at defining COPD phenotypes, it 
was observed that exacerbations became more frequent as the level of airflow obstruction increased 
14. In this longitudinal study exacerbation rates in the first year of follow-up varied from 0.85 per 
person for patients with GOLD stage 2, 1.34 for patients with stage 3 and 2.00 for patients with stage 
4.  
However, the single best predictor of exacerbations, across all GOLD stages, was a history of frequent 
exacerbations. A distinct frequent-exacerbation phenotype could be identified, that appeared to be 
relatively stable over a period of 3 years. It has been previously established that patients in this 
subgroup with frequent exacerbations have a poorer quality of life 34, and a faster decline in lung 
function 35, 36.  
 
Time course of exacerbations 
 
Exacerbations of COPD have a sharp increase of symptoms after a short prodromal stage with 
respiratory symptoms, followed by a slow recovery of weeks to months 5, 37. The lasting impact of 
exacerbations was shown in the study by Spencer et al 38. In this study duration of worsening health 
status up to several months after a COPD exacerbation has been demonstrated. Depressive 
symptoms at admission have a negative impact on recovery and are related to worse survival and 
increased risk for subsequent exacerbations 39. The COPD assessment test (CAT) and Clinical COPD 
Questionnaire (CCQ) are useful tools to evaluate recovery after an exacerbation 40. 
 
Seasonality 
 
Exacerbations occur more frequently during winter months 6. It has been reported that exacerbations 
were associated with colder outdoor temperature 41. The seasonal pattern has a marked impact on 
exacerbation outcomes, antibiotic treatment and all-cause mortality 42. We showed that viral 
infections are an important cause of this seasonality 43. 
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5. Impact of COPD exacerbations 
 
Mortality 
 
Between 1990 and 2010, chronic obstructive pulmonary disease (COPD) moved from the fourth to 
third most common cause of death worldwide 44. 
It has been shown that acute exacerbations of COPD have been associated with an increased risk of 
death 45, 46. Mortality increases with the frequency of severe exacerbations, which require admission 
to hospital 45. Mortality following hospitalization for an acute exacerbation of COPD varies between 
23% 47
 
and 80% 48.  
 
Hospital admissions 
 
Acute exacerbations of COPD are a significant cause of hospital admission worldwide 49. 
Information about the appropriateness of hospitalization among patients experiencing exacerbations 
of COPD is scarce 50. 
Several guidelines describe the management of patients with COPD and exacerbations 51-53. 
Appropriate criteria to identify patients who are more likely to benefit from admission in terms of 
mortality and COPD progression have been validated 54. 
 
Health care costs 
 
Exacerbations of COPD account for a substantial portion of COPD related costs 55. Increasing 
exacerbation frequency is associated with a multiplicative increase in all cause and COPD related 
costs 56. Exacerbation prevention and treatment strategies may be a key strategy in COPD disease 
management in order to reduce costs 56.The optimal duration of hospitalization in individual patients 
with an exacerbation of COPD has not been established 57. 
 
Quality of life 
 
One of the main objectives in the management of patients with COPD is to preserve or improve their 
health status 58. It has been shown that even in patients with mild COPD the health related quality of 
life (HRQL) can be substantially compromised59. Exacerbations lead to a short term deterioration in 
HRQL 60. However, long term negative effects have also been established 34, especially in patients 
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with frequent exacerbations 6. In order to optimize HRQL it is crucial to develop strategies to prevent 
COPD exacerbations. 
 
Lung function 
 
Several studies have shown that exacerbations play a role in the decline in FEV1 35, 36, 61. 
Data from the Lung Health Study showed that lower respiratory illnesses promote FEV1 decline in 
current smokers but not ex-smokers with mild chronic obstructive pulmonary disease 35. Donaldson 
et al showed a relationship between the frequency of exacerbations and long term decline in lung 
function of patients with moderate to severe COPD 36. 
 
6. Management 
 
Bronchodilators 
 
Bronchodilators are useful in mild, moderate and severe exacerbations62. Mild exacerbations are 
defined as an acute worsening of respiratory symptoms, that result in treatment with short acting 
bronchodilators 63. It is also recommended to start long-acting bronchodilators during an 
exacerbation, although there are no clinical studies to support this 62. 
 
Systemic corticosteroids 
 
 The use of systemic glucocorticoids in COPD exacerbations improves lung function and leads to a 
shorter recovery time 62. Treatment leads also to less treatment failure 64 and a shorter duration of 
hospitalization 65, 66. 
 
Antibiotics 
 
It  is still under debate if antibiotics should be used during exacerbations 62. It appears that outcome 
is improved in moderate to severe COPD in patients who have symptoms of an airway infection 67-69. 
The clinical efficacy has also been shown in patients requiring mechanical ventilation 70. 
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Oxygen 
 
It is recommended to start titrated oxygen treatment with a target saturation of 88-92%, in acute 
exacerbations of COPD in order to reduce mortality, hypercapnia, and respiratory acidosis  71.  
 
Noninvasive ventilation 
 
Non invasive ventilation (NIV) is superior to invasive ventilation as the initial mode of ventilation in 
COPD patients with acute respiratory failure, with a success rate of 80-85% 72-74. NIV reduces 
mortality and intubation rates in these patients 75, 76. 
 
7. Prevention 
 
The prevention of exacerbations is a major goal in the management of COPD patients 62. In order to 
reduce exacerbation frequency, pharmacological and non-pharmacological interventions are 
available 77.  
 
Smoking cessation 
 
Smoking cessation is associated with a significantly reduced risk of COPD exacerbations even after 
adjusting for age, comorbidity, markers of COPD severity and socio-economic status and the 
described reduction is dependent upon the duration of abstinence 78. 
 
Vaccinations 
 
Vaccination against influenza has proven to be protective in the prevention of influenza related 
airway diseases and reduced the total number of exacerbations per patient 79. The evidence of 
pneumococcal vaccination is conflicting 80-82. It has been shown that 23-valent pneumococcal 
polysaccharide vaccine is effective in preventing community acquired pneumonia in patients with 
COPD aged less than 65 years and in those with severe airflow obstruction. However, no differences 
were found among the other groups of patients with COPD 80. In a Cochrane review it was concluded 
that injectable polyvalent pneumococcal vaccines may provide some protection against morbidity in 
persons with COPD, but no significant effect on any of the outcomes could be shown 81. 
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Lung volume reduction surgery 
 
In patients with severe COPD lung volume reduction surgery reduces the frequency of COPD 
exacerbations and increases the time to first exacerbation 83. This effect has not yet been shown by 
the use of bronchoscopic lung volume reduction techniques 84. 
 
Physical activity/pulmonary rehabilitation 
 
It has been proven that patients with COPD who perform some level of regular physical activity have 
a lower risk of both COPD admissions and mortality 85. Also, evidence suggests that pulmonary 
rehabilitation is a highly effective intervention to reduce hospital admissions and mortality in COPD 
patients who have recently suffered an exacerbation of COPD 86. However, one study showed that 
early rehabilitation during hospital admission for chronic respiratory disease did not reduce the risk 
of subsequent readmission following the event over 12 months. Moreover, mortality at 12 months 
was higher in the intervention group 87. 
 
Long-acting bronchodilators 
 
Bronchodilators clearly have a role in the prevention of COPD exacerbations. Long acting anti-
muscarinic agents (LAMAs) and long acting β agonists (LABAs) not only improve expiratory airflow, 
but have also shown to reduce the risk of moderate to severe exacerbations by 22-34% 12, 88-91. 
Treatment with LAMA is superior to LABA in reducing exacerbations 92, 93. There are results that 
indicate that a LABA/LAMA combination is superior in preventing moderate to severe COPD 
exacerbations compared with a single long-acting bronchodilator 94. 
 
Inhalation corticosteroids (ICS) 
 
Inhalation corticosteroids (ICS) are effective in reducing the number and severity of COPD 
exacerbations 95, 96. In the TOwards a Revolution in COPD Health (TORCH) trial, investigating the 
combination of salmeterol/fluticasone propionate for 3 years in COPD on all-cause mortality, 
treatment with fluticasone resulted in an 18% reduction in exacerbation rate compared with placebo 
97. However, a meta-analysis showed only a modest benefit of ICS in preventing COPD exacerbations 
98. Therefore, in guidelines monotherapy with inhaled corticosteroids is not recommended 62. 
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Combinations of ICS and long-acting bronchodilators 
 
 In the TORCH study it was found that an ICS combined with LABA is more effective in reducing COPD 
exacerbations when compared with placebo, but also when compared with LABA alone 97. 
There is conflicting evidence about the benefits of triple therapy (inhaled corticosteroid-LABA plus 
LAMA) compared to LABA/LAMA on reducing the number of exacerbations 99, 100. 
Triple therapy can be considered in patients on LABA/LAMA therapy who develop further  
exacerbations 62. 
 
Phosphodiesterase-4 inhibitors 
 
It has been shown that the selective phosphodiesterase 4-inhibitor roflumilast reduced COPD 
exacerbations in a subpopulation of patients with symptoms of chronic bronchitis (chronic cough and  
sputum production) and a history of exacerbations compared with placebo 101. 
 
It can be concluded that these preventive measures have a limited effect on exacerbation frequency. 
There is still a need for interventions, which further reduce exacerbation frequency, especially in 
patients with frequent exacerbations.  
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Abstract 
 
In the natural course of chronic obstructive pulmonary disease (COPD), exacerbations are important 
events influencing the outcome. Pharmacological and nonpharmacological interventions are 
available to reduce the exacerbation frequency. Despite these strategies to reduce exacerbations of 
COPD, there is still a subgroup of COPD patients who are experiencing exacerbations of COPD. 
Macrolide antibiotics may be an alternative therapy in this distinct subgroup of patients. This review 
describes the current understanding of the value of maintenance therapy with macrolides to reduce 
COPD exacerbations, according to recent studies. The positioning of macrolides in addition to the 
usual care, patient selection, and treatment regimen are discussed. 
 
Introduction 
 
In the natural course of COPD, exacerbations are important events influencing outcome. They cause 
a more rapid decline in lung function 37, worsening of the quality of life 35 and increased mortality 45. 
Therefore, prevention of exacerbations is a major goal in the management of COPD patients 53. 
Pharmacological and non-pharmacological interventions are available in order to reduce 
exacerbation frequency 64. 
Bronchodilators clearly have a role in the prevention of COPD exacerbations. Long acting 
antimuscarinic agents (LAMAs) and long acting β agonists (LABAs) not only improve expiratory 
airflow, but have also shown to reduce the risk of moderate to severe exacerbations by 22-34% 74-78. 
In the TORCH study it was found that inhaled corticosteroid-LABA combination inhalers significantly 
reduced COPD exacerbations when compared with placebo, but also when compared with LABA 
alone 76. These findings were confirmed in other studies 91. 
The use of triple therapy (inhaled corticosteroid-LABA plus LAMA) may have an additional effect by 
reducing the number of severe exacerbations 92. 
Clinical trials have shown that the selective phosphodiesterase 4-inhibitor roflumilast reduced COPD 
exacerbations in a subpopulation of patients with symptoms of chronic bronchitis (chronic cough and 
sputum production) that have had at least one exacerbation within the past year. In this subgroup, it 
was shown that roflumilast reduced exacerbations by 17% compared with placebo 95. 
Prospective studies on the long-term effects of systemic corticosteroids in COPD are limited and 
show no reduction in exacerbation frequency 53. 
Non-pharmacological strategies include influenza vaccination, self-management programs, 
pulmonary rehabilitation and lung volume reduction surgery (LVRS). Vaccination against influenza 
has proven to be protective in the prevention of influenza related airway diseases and reduced the 
  
 
Macrolides for reducing COPD exacerbations | 27 
total number of exacerbations per patient 66. In some patients with severe COPD LVRS reduces the 
frequency of COPD exacerbations and increases the time to first exacerbation 70. 
Despite above strategies to reduce exacerbations of COPD, there is still a subgroup of COPD patients 
who are experiencing exacerbations of COPD. Therefore, there is a need to generate alternatives to 
prevent exacerbations in this distinct subgroup of patients. Macrolide antibiotics may be an 
alternative therapy in this type of patients. This review describes the current understanding of the 
value of maintenance therapy with macrolides to reduce COPD exacerbations, according to recent 
studies. 
 
Trials with macrolides in COPD 
 
The effect of macrolides in the treatment of COPD has been evaluated in several studies. We 
described the results of these studies in an earlier overview 96. The most recent prospective 
randomized trials are summarized in Table 1. These recent studies have been set up as double 
blind randomized controlled trials, in contrast to the majority of the older studies 97-99. 
 
New evidence 
 
Seemungal et al performed a randomized double-blind placebo-controlled trial in patients with COPD 
to determine whether regular therapy with macrolides reduces exacerbation frequency 97.  Patients 
with moderate to severe COPD (FEV 1 between 30% and 70% of predicted) were included. Exclusion 
criteria were a history of asthma, bronchiectasis, neoplasia, or other significant respiratory disease. A 
total of 109 outpatients were randomized to receive 250 mg erythromycin or placebo twice daily 
over 12 months. The main result was a significant difference in median exacerbation frequency in 
one year: 2 in the placebo group versus 1 in the erythromycin group (p=0.006). The time to the first 
exacerbation was significantly lower in the macrolide arm compared with the placebo arm (271 vs. 
89 days). Furthermore, patients in the macrolide arm had shorter duration of exacerbations 
compared with placebo. 
Albert et al performed the largest prospective study concerning long-term macrolide therapy in 
COPD 98.  
They performed a randomized placebo-controlled double-blind trial in COPD patients who had an 
increased risk of exacerbations to evaluate whether azithromycin decreased the frequency of 
exacerbations. Inclusion criteria were treatment with systemic glucocorticoids for an AECOPD in the 
previous year or the use of continuous supplemental oxygen. Asthma was one of the exclusion 
criteria. The primary outcome was the time to the first AECOPD. A total of 1142 patients were 
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randomly assigned to receive azithromycin at a dose of 250 mg daily or placebo for 12 months in 
addition to usual care. The median time to first exacerbation was 266 days (95% CI, 227-313) among 
participants receiving azithromycin, as compared with 174 days (95% CI, 143-215) among 
participants receiving placebo (p<0,001). The scores on the St. George’s Respiratory questionnaire 
improved more in the azithromycin group than in the placebo group (p=0,004), although the mean 
change did not exceed the minimal clinically important difference for the group. No differences were 
seen between groups in the score on the Medical Outcomes Study 36-Item Short-Form Health 
Survey. This study showed that azithromycin decreased exacerbation rate in selected patients with 
COPD.  
Uzun et al have published the most recent prospective study concerning long-term macrolide 
therapy 99.  
In contrary to the two previous studies we included COPD patients with the frequent exacerbator 
phenotype. The aim of our study was to investigate whether COPD patients who had received 
steroids or antibiotic treatment for three or more exacerbations in the previous year would have a 
decrease in exacerbation rate when maintenance treatment with azithromycin was added to 
standard care. 
The study was a randomised, double-blind, placebo-controlled, single-centre trial. The primary 
endpoint was the rate of exacerbations of COPD in the year of treatment. Main exclusion criteria 
were a history of other clinically significant respiratory diseases (eg, asthm a, cystic fibrosis) and 
presence of bronchiectasis. To exclude patients with bronchiectasis a CT scan was performed in all 
included patients. After randomization patients received either azithromycin 500 mg or placebo, 
three times a week (Monday, Wednesday, and Friday) for 12 months. Analysis was by intention to 
treat. 92 patients were randomly assigned to the azithromycin group (n=47) or the placebo group 
(n=45). 
The unadjusted exacerbation rate per patient per year was 1·94 (95% CI 1·50–2·52) for the 
azithromycin group and 3·22 (2·62–3·97) for the placebo group. After adjustment, azithromycin 
resulted in a significant reduction in exacerbation rate versus placebo (0·58, 95% CI 0·42–0·79; 
p=0·001). The median time to first exacerbation was 59 days (95% CI 31–87) in the placebo group 
and 130 days (28–232) in the azithromycin group (p=0·001). In the year of treatment the odds for 
hospital admission due to acute exacerbations of COPD did not differ between groups (O R 1·34, 
95% CI 0·67–2·70; p=0·41).  
We concluded that maintenance treatment with azithromycin significantly decreased exacerbation 
rate and increased time to first exacerbation compared with placebo and should therefore be 
considered for use in patients with COPD who have the frequent exacerbator phenotype and are 
refractory to standard care. 
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Table 1 Overview of Recent Trials 
 Seemungal et al 97 Albert et al 98 Uzun et al 99 
Design of study RCT RCT RCT 
Double blind Yes Yes Yes 
No. Patients 
(treatment-control) 
109 (53-56) 1142 (570-572) 92 (47-45) 
No. Males (%) 69 (60) 651 (57) 40 (43) 
Mean age, 
treatment-control 
67-68 65-66 65-65 
Inclusion criteria of 
 COPD severity 
FEV1 between 30%  
and 70% of predicted 
FEV1 < 80% of predicted  
FEV1/FVC ratio <70% 
 FEV1/FVC ratio <70% 
Mean FEV1 in % of 
predicted, 
treatment-control 
49-51 39-40 44-45 
Macrolide dose Erythromycin 250 mg  
twice daily 
Azithromycin 250 mg  
daily 
Azithromycin 500 mg  
three times a week 
Duration of therapy 
(mo) 
12 12 12 
RCT = randomized controlled trial 
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Working mechanism of macrolides 
 
Besides antimicrobial effects, macrolides have anti-inflammatory and anti-viral effects 100-106 
Since COPD exacerbations are mainly caused by bacterial and viral infections, leading to 
airway inflammation, macrolides can be useful in the treatment and prevention of 
exacerbations 107. 
 
Antibacterial effects 
 
The main antimicrobial effect of macrolides is inhibition of bacterial protein synthesis, by 
binding to the 50S subunit of the bacterial ribosome 108. Macrolides mainly affect gram-positive 
bacteria and intracellular pathogens such as Mycoplasma, Chlamydia and Legionella 108. Azithromycin 
is also effective against gram-negative organisms, such as Haemophilus influenzae 108. 
A decrease in airway bacterial colonisation in patients receiving maintenance treatment with 
azithromycin may lead to a reduction in systemic inflammation 109. 
Besides a direct antimicrobial effect, macrolides also modulate the virulence and the inflammation 
caused by the bacteria that induce COPD exacerbations.  Studies have shown that macrolides 
influence the virulence of microorganisms, like Proteus mirabilis 110, S. pneumonia 111 and H. 
influenzae 112. Clarithromycin reduces the production of pneumolysin, a key virulence factor in the 
infection of S. pneumonia 111. Furthermore, the production of pro-inflammatory cytokines, soluble 
intercellular adhesion molecule (ICAM)-1 and mucin in airway epithelial cells in response to 
endotoxin and extract of H. influenzae is reduced by macrolides 101,113. In addition, macrolides may 
reduce the production of exoenzymes 114. 
Many studies have been performed investigating the mechanisms of action of macrolides in P. 
aeruginosa infections. Azithromycin maintains the integrity of airway epithelial cells during P. 
aeruginosa infection 115. Macrolides alter the biofilm around bacteria 112,116. In P. aeruginosa this may 
facilitate phagocytosis by polymorphonuclear neutrophils 117. Furthermore, It has been suggested 
that macrolides block quorum sensing 118 in P. aeruginosa, which relates to virulence factor 
production 119.  In P. aeruginosa, macrolides reduce flagellin synthesis and expression 120,121, thereby 
inhibiting the twitching motility 116.  
 
Antiviral effects 
 
During COPD exacerbations, viruses (most commonly rhinovirus, influenza virus and respiratory 
syncytial virus) cause injury to epithelial cells with subsequent pulmonary edema, alveolar 
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destruction and airflow limitation 107. Macrolides exert their antiviral function through the inhibitory 
action against virus-induced inflammatory responses in the lung. Most of these effects have been 
studied in murine models and in in vitro studies. 
It was also demonstrated that clarithromycin suppressed the growth of the influenza virus and its 
release in mouse airways and epithelial cells 104. Furthermore, Yamaya et al. showed that 
clarithromycin decreased the release of viruses and cytokines into supernatant fluids in human 
tracheal epithelial cells that were infected with type A seasonal influenza (H3N2) 106. This effect was 
achieved by reducing the expression of the viral receptor and by inhibiting viral RNA entry. 
Gielen reported that interferons were induced in human bronchial epithelial cells when the cells 
were pretreated with azithromycin and infected with rhinovirus 122. In this study azithromycin 
reduced rhinovirus replication and release. This effect may relate to the shorter duration of 
exacerbations in COPD patients who are treated with macrolides. Another study showed that 
azithromycin could reduce rhinovirus replication in CF bronchial epithelial cells compared to cells 
from control children 123. Asada et al. also reported that macrolides have inhibitory effects on RSV 
virus infection in human airway epithelial cells 105. 
To date, the only study investigating the antiviral effect of macrolides in humans was performed by 
Suzuki et al 124. In this study the efficacy of erythromycin therapy for the prevention of the common 
cold and subsequent exacerbations in COPD was evaluated in a prospective, randomized controlled, 
but not blinded, trial. The relative risk of developing two or more common colds in the control group 
compared with that in the erythromycin group was 9.26 (95% confidence interval, 3.92 to 31.74; p = 
0.0001). The relative risk of experiencing a COPD exacerbation in the control group compared with 
that in the erythromycin group was 4.71 (95% CI, 1.53 to 14.5; p = 0.007). 
 
Immune modulatory effects 
 
The immune modulatory effects of macrolides have been extensively investigated. Since COPD 
exacerbations seem to be related to an underlying pro-inflammatory state with an over-activated 
immune system macrolides may play a role in the treatment of COPD exacerbations 125.  
Takizawa et al. 126 and Desaki et al. 127 demonstrated that macrolides had effects on bronchial 
epithelial cells. The results indicated that erythromycin had inhibitory effects not only on the mRNA 
expression and release of IL-8, but also on the activation of transcription factors nuclear factor-κB 
and activator protein-1. 
Furthermore, the function of dendritic cells in T -cell regulation can be modulated by macrolides 128.  
Airway infiltration by neutrophils in response to activation of alveolar macrophages in bacterial and 
viral infections is an important feature of lung inflammatory reactions and is involved in most lung 
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pathologies 129. Erythromycin was able to inhibit neutrophil chemotaxis by decreasing the expression 
of adhesion molecules and chemoattractants 101. Azithromycin was able to reduce the concentrations 
of G-CSF within the airways 130. This activity may result in a decrease in epithelial cells-dependent 
neutrophil survival within the airways. 
In vitro studies have demonstrated that macrolide antibiotics such as erythromycin 131, 
clarithromycin 131 and azithromycin 113 have inhibitory effects on mucin or MUC5AC production or 
secretion in airway epithelial cells, thereby inhibiting mucus hypersecretion. Shimizu et al. 131 
reported that clarithromycin inhibited ovalbumin (OVA)- and lipopolysaccharide (LPS)-induced mucus 
production in rats. 
 
Macrolide resistance 
 
Mechanisms of bacterial resistance to macrolides 
 
There are two common mechanisms of macrolide resistance in streptococci (Figure 1). The first 
mechanism is the M phenotype. In this mechanism activation of the efflux pump removes macrolide 
antibiotics from the cell. The M phenotype is mediated by the MEF (A) gene. The M phenotype 
usually results in moderate macrolide resistance 132. The second mechanism is the MLSB (macrolide, 
lincosamide, and streptogramin) resistance phenotype. This is the result of erm (erythromycin 
ribosome methylase) gene mutations. These mutations, lead to ribosomal target modification for 
these antibiotics, preventing binding and activity. Erm B gene mutation is the most prevalent 
pneumococcal macrolide resistance genotype 133. Erm (B) gene mutation is also commonly found in 
bacteria other than pneumococcus 132. 
 
Macrolide resistance in response to macrolide antibiotic exposure 
 
The development of macrolide resistance related to treatment with macrolide antibiotics is a major 
concern 134. 
It has been shown that macrolide resistance develops in response to macrolide antibiotic exposure 
134. Since the introduction of long-acting macrolides, such as azithromycin, macrolide resistance rates 
are increasing in the United States and Europe 135,136. It has been demonstrated that on a population-
level, an increase in macrolide exposure results in higher macrolide resistance rates 135. However, 
exposure to macrolides can lead to macrolide resistance on an individual level as well. This effect has 
been observed after short-term 137 and long-term use of macrolide antibiotics 138. 
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Several studies have shown that azithromycin use is also related to increased resistance to other 
antibiotic classes, especially to penicillin 136.  
However, it is difficult to judge the independent effect of macrolides from these studies. 
In the study by Uzun et al the acquisition of macrolide resistant bacteria in sputum has been 
identified 99. The number of positive sputum cultures was low. In line with Albert and colleagues’ 
findings 98, patients in the azithromycin group were less likely to become colonized with respiratory 
pathogens than were those in the placebo group. Furthermore, azithromycin significantly reduced 
acquisition of macrolide-resistant bacteria in sputum compared with placebo. In this study, the 
increase in acquisition of macrolide-resistant bacteria in the placebo group could not be explained by 
additional use of macrolides during follow-up for any indication. A limitation of this study was the 
fact that macrolide resistance has not been assessed in oral commensal flora. Therefore, the results 
might underestimate macrolide resistance in vivo.  
 
New techniques to detect microbial resistance 
 
The human body serves as a host for a wide range of microorganisms, which has been termed the 
microbiota 139. The micobiome is the aggregate collection of genes within the microbiota. The portion 
which encodes resistance to antibiotics is called the resistome 140. There is evidence that the use of 
antibiotics has an impact upon the composition of the resistome 141. Recently new PCR-based 
techniques have been developed that provide insight into antibiotic resistance 142. With these so-
called metagenomic approaches, the presence of antimicrobial resistance (AMR) genes can be 
detected. These non-culture based techniques are used to avoid potential bias associated with 
difficult to culture bacteria. 
Consequently, the composition of the resistome and the changes in response to antibiotic therapy 
can be monitored more accurately 143. At present these data are lacking in patients on macrolide 
treatment. 
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Figure 1: The two most common mechanisms of macrolide resistance in pneumococcus 
 
From: Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use 
for inflammatory airway diseases. The Lancet Respiratory medicine. 2013; 1(3):262-74 
 
Relevant aspects of treatment with macrolides 
 
The use of azithromycin for the prevention of COPD exacerbations has not been endorsed by current 
expert guidelines. 
Although there is emerging evidence about the efficacy of maintenance therapy with macrolides in 
the prevention of AECOPD 97-99, uncertainty remains about several aspects of this treatment. 
Positioning of macrolides in addition to usual care, patient selection and treatment regimen, must be 
considered as part of the risk-benefit ratio of this treatment. The different aspects and 
recommendations are summarized in table 2. 
 
Positioning of macrolides in addition to usual care 
 
As already mentioned, the use of inhaled corticosteroids (ICS) 76, LAMAs 74, LABAs 77 and selective 
phosphodiesterase 4-inhibitors 95, may reduce the exacerbation frequency in selected sub-groups of 
patients with COPD with 12-34%. Non-pharmacological strategies, including influenza vaccination, 
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pulmonary rehabilitation and lung volume reduction surgery (LVRS) also have proven to be effective 
in reducing the number of exacerbations per patient 66,70. 
It can be hypothesized that with macrolide maintenance therapy an additional reduction in 
exacerbation frequency can be achieved. In the study of Seemungal et al there was no statistically 
significant difference between the macrolide and placebo arms in ICS use or dosage 97. A significant 
reduction in exacerbation rate was found in the macrolide arm compared with the placebo arm. It 
was suggested that the effect of the macrolide (erythromycin) occurred on top of any effect of ICS on 
reducing exacerbation frequency.  
In the study by Albert et al there were also no significant between-group differences with regard to 
the use of ICS, LAMAs and LABAs 98. Subgroup analyses showed that the response to azithromycin 
seemed to vary according to age (≤65 vs. >65 years), smoking status (former smoker vs. current 
smoker), use or nonuse of oxygen, GOLD stage, and use of ICS. The use of ICS at enrollment was 
associated with a decreased effect of azithromycin on the time to first AECOPD. 
Uzun et al examined a COPD population that was refractory to usual care 99. A large part of the 
population received treatment with ICS (92%), LABAs (93%) or LAMAs (80%). Hence, it can be 
assumed that macrolide treatment reduced the exacerbation frequency in this highly selected group 
of patients on top of the effects of inhalation medication. Furthermore, in this study it was 
demonstrated that there was no statistically significant difference in the exacerbation rate ratio of 
azithromycin treatment to placebo between patients who did and did not already receive long-term, 
low-dose prednisolone treatment (p=0.12) 
 
Patient selection 
COPD is a common disease with a reported prevalence of approximately 10% 144. Widespread use of 
macrolide treatment has the potential to greatly affect population macrolide resistance rates 134. 
The large size of this patient population makes it necessary to choose the right criteria on the basis of 
which patients will be treated with azithromycin maintenance therapy.  
 
Treatment of contributing factors 
It is suggested that only COPD patients in whom other contributing factors, such as smoking, have 
been optimally managed should be considered for macrolide treatment 134. 
 
Exacerbation frequency 
The greatest benefit of treatment with macrolides can be achieved in COPD patients with frequent 
exacerbations in the past year. This also provides a baseline against which a clinical response can be 
assessed. Therefore it has been recommended by Wenzel to consider long-term azithromycin 
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treatment only in selected COPD patients with at least two exacerbations in the previous year 145. 
Several studies have shown that an exacerbation frequency greater than three per year is associated 
with a greater rate of FEV1 decline 37. These findings were the reason to choose 3 or more 
exacerbations in the previous year as inclusion criterion in the study by Uzun et al 99. In this study a 
higher relative reduction in exacerbation rate (42%) was recorded compared to the trials of 
Seemungal and colleagues (35%) 97 and Albert and colleagues (27%) 98. In the study by Albert et al 
12% of patients did not have any exacerbation in the year before inclusion 98. Moreover, this was also 
seen in 32% of patients in the control group during the study, compared with 7% in the control group 
of the study by Uzun et al 99. Therefore, the use of a criterion of three or more exacerbations exposes 
fewer patients to redundant macrolide treatment and results in a substantial clinical benefit. 
 
Side effects/drug interactions 
Ototoxicity, cardiac toxicity, and drug interactions are the three major categories of adverse effects 
that may be anticipated with long-term treatment with azithromycin 145. Albert and colleagues found 
a 5% differential in hearing loss between the azithromycin group (25%) and the placebo group (20%). 
In the study by Uzun et al patients were actively asked about hearing loss, but no standard 
audiometry was performed 99. At the end of the study, one patient in the placebo group reported 
hearing loss. Seemungal and colleagues did not perform routine screening of hearing as this was not 
thought to be a significant side effect at this dose of macrolide 97. 
Macrolide antibiotics are known to cause ventricular arrhythmias 145. In recent studies with long-term 
macrolides, patients with an unstable cardiac status (e.g., cardiac failure, prolonged QTc interval, 
cardiac arrhythmia or tachycardia) were excluded 97-99. In a recent review it was concluded that this 
risk was overestimated and chronic macrolides can be used safely in the majority of COPD patients 
146. 
Macrolides inhibit the cytochrome P-450 CYP3A4 isoenzyme and cause increased serum levels of 
other drugs metabolized by this enzyme 145. Patients taking any drug that are metabolized by this 
enzyme are recommended to avoid long-term macrolides 147.  
 
Treatment regimen 
 
Dose 
In two recent studies COPD patients received long-term treatment with macrolides on a daily basis 
97,98. 
In the study by Seemungal and colleagues long-term erythromycin 250 mg was administered twice 
daily to COPD patients 97. Albert et al also treated COPD patients with daily macrolides (azithromycin 
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250 mg) 98. 
However, with a three times weekly regimen, tissue levels of azithromycin are sufficient for a 
bactericidal effect 148. Furthermore, studies involving patients with cystic fibrosis and bronchiectasis 
showed that the side effects of azithromycin were fewer when a reduced regimen (three times per 
week instead of daily) was used 149. This regimen (azithromycin 500 mg three times a week) was used 
in COPD patients in the recent study by Uzun et al and resulted in a significant reduction of the 
exacerbation rate compared with placebo 99.  
 
Which macrolide 
Azithromycin is the most studied macrolide in long-term treatment in patients with cystic fibrosis, 
bronchiectasis and COPD and has fewer adverse effects compared with other macrolides 145. In two 
out of three recent studies with COPD-patients azithromycin was the drug of choice 98,99. 
 
Duration of long-term treatment 
In the three recent clinical trials of Seemungal et al, Albert et al and Uzun et al, patients received 
treatment with macrolides during a one-year period 97-99. It is unclear whether maintenance therapy 
with macrolides should be continued after this first year in case of a relevant reduction of the 
number of exacerbations. Further studies with different treatment regimens and longer treatment 
duration should provide an answer to this question. 
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Table 2 Treatment guidelines for long-term macrolide treatment in COPD patients 
Subject Recommendation 
Positioning in addition to usual care  
Pharmacological treatment ICS, LABAs, LAMAs 
Non-pharmacological treatment Influenza vaccination 
 Pulmonary rehabilitation program 
Patient selection  
Treatment of contributing factors Smoking cessation 
Exacerbation frequency ≥ 3 exacerbations in the previous year 
Side effects/drug interactions  
Ototoxicity No hearing impairment 
Cardiac toxicity Normal QTc interval 
 No use of drugs known to cause QT prolongation 
Cytochrome P-450 CYP3A4 isoenzyme inhibition No use of drugs that are metabolized by this enzyme 
Treatment regimen  
Dose Azithromycin 500 mg three times a week 
Duration of treatment 1 year 
 
 
Conclusions 
 
On the basis of recent studies, macrolides can be used as maintenance therapy in COPD patients with 
3 or more exacerbations in the previous year. Treatment should only be considered in patients in 
whom other contributing factors have been optimally managed and maximum therapy 
(pharmacological and non-pharmacological) has been used. 
Side effects and interactions with other medication must be taken into account. 
Azithromycin should be the drug of choice with a dose of 500 mg 3 times a week and duration of 
treatment of 1 year, pending the results of future studies. 
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Abstract 
 
Background 
Chronic obstructive pulmonary disease (COPD) is characterised by progressive development of 
airflow limitation that is poorly reversible. Because of a poor understanding of COPD pathogenesis, 
treatment is mostly symptomatic and new therapeutic strategies are limited. There is a direct 
relationship between the severity of the disease and the intensity of the inflammatory response. 
Besides smoking, one of the hypotheses for the persistent airway inflammation is the presence of 
recurrent infections. Macrolide antibiotics have bacteriostatic as well as anti-inflammatory properties 
in patients with cystic fibrosis and other inflammatory pulmonary diseases. There is consistent 
evidence that macrolide therapy reduces infectious exacerbations, decreases the requirement for 
additional antibiotics and improves nutritional measures. Because of these positive effects we 
hypothesised that maintenance macrolide therapy may also have beneficial effects in patients with 
COPD who have recurrent exacerbations. The effects on development of bacterial resistance in 
patients with COPD to macrolides due to this long-term treatment are unknown. 
Until now, studies investigating macrolide therapy in COPD are limited. The objective of this study is 
to assess whether maintenance treatment with macrolide antibiotics in COPD patients with three or 
more exacerbations in the previous year decreases the exacerbation rate in the year of treatment 
and to establish microbial resistance due to the long-term treatment. 
 
Methods/design 
The study is set up as a prospective randomised double-blind placebo-controlled single-centre trial. A 
total of 92 patients with COPD who have had at least three exacerbations of COPD in the previous 
year will be included. Subjects will be randomised to receive either azithromycin 500 mg three times 
a week or placebo. Our primary endpoint is the reduction in the number of exacerbations of COPD in 
the year of treatment. 
 
Discussion 
We investigate whether long-term therapy with macrolide antibiotics can prevent exacerbations in 
patients with COPD. Additionally, our study aims to assess the effect of long-term use of macrolides 
on the development of antimicrobial resistance and on inflammatory parameters related to COPD. 
We believe this study will provide more data on the effects of macrolide treatment in patients in 
COPD and will add more knowledge on its working mechanisms. 
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Background 
 
Chronic obstructive pulmonary disease (COPD) is generally accepted to become one of the major 
health problems in the western worlds in the following years. The main issue is the progressive 
character of the disease, which is characterised by an ongoing development of non-reversible airflow 
limitation. 
COPD imposes a substantial burden on health-care systems worldwide, as the disease is a major 
cause of morbidity, mortality, reduced health status and a common cause of medical hospital 
admission.1 Because of a poor understanding of COPD’s pathogenesis, treatment is mostly 
symptomatic and new therapeutic strategies are limited. One of the known causes of COPD is long-
term exposure to noxious particles or gasses. Particularly cigarette smoking is one of the main causes 
of development of COPD.2 All smokers show evidence of lung inflammation, but smoking-induced 
lung injury is variable and appears to be amplified only in a minority of long-term tobacco smokers, 
suggesting that superimposed processes are the final determinants of COPD development.3,4 There is 
a direct relationship between the severity of the disease and the intensity of the inflammatory 
response.3,4 Thus, excessive inflammation is likely the key to susceptibility. Inflammation persists long 
after patients have stopped smoking. The cause of this persistent airway inflammation is unknown 
although recurrent airway infections seem to play a role in this process. 
Macrolide antibiotics have bacteriostatic as well as anti-inflammatory properties.5-7 The anti-
inflammatory capacities of macrolides were firstly established in pulmonary diseases as diffuse 
panbronchiolitis, a progressive inflammatory disorder of the airways found almost exclusively in 
Japan.7 Also in patients with cystic fibrosis macrolide therapy had led to improvement of several 
clinical parameters.8-13 
Although currently the use of maintenance antibiotic treatment in COPD, other than for treating 
infectious exacerbations COPD, is not recommended by the GOLD report.14 Several studies have been 
conducted to assess the effect of long-term therapy with macrolide antibiotics in patients with 
COPD.15-17 The results of these studies are conflicting; however some suggest that macrolide 
antibiotics may become a valuable therapeutic option for COPD patients in preventing exacerbations. 
In this randomised placebo controlled trial our main aim is to assess whether maintenance treatment 
with three times weekly azithromycin in COPD patients with three or more exacerbations in the 
previous year can decrease the exacerbation rate in the year of treatment and to study the effect of 
this treatment on microbial resistance. 
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Methods 
 
The study is designed as a prospective randomised double-blind placebo-controlled single-centre trial 
in the department of respiratory medicine in the Amphia Hospital Breda, The Netherlands. Length of 
study is determined at a period of 3 years, of which 2 years will be spent on patient inclusion and 1 
year on treatment. The end of the study is defined by the last visit of the last included subject. 
 
Patient selection 
 
All patients with COPD who have had three or more exacerbations in the previous year will be asked 
to participate in the study. An exacerbation of COPD is defined by a (sub)acute increase of pulmonary 
symptoms like dyspnoea, coughing, increased sputum volume with or without purulence, for which 
the patient has consulted a general practitioner (GP) or a respiratory physician, or for which the 
patient has been admitted to the hospital. The health care professional has judged the symptoms to 
be in such a degree that treatment was given with systemic steroids and/or a course of antibiotics. 
The patients will be recruited from the outpatient department. To assess whether the patient fulfils 
the criteria for study participation the study subjects’ GP will be contacted to review the patient 
chart and medication use. The hospital charts will be reviewed as well by the investigator. 
 
Inclusion criteria 
 
- Diagnosis of COPD according to GOLD criteria (FEV1/FVC < 70%), classification into GOLD I 
(FEV1 8-100% predicted), GOLD II (FEV1 50-80% predicted), GOLD III (FEV1 30-50% predicted) 
or GOLD IV (FEV1 ≤ 30% predicted). 
- Age ≥ 18 years 
- Three or more exacerbations of COPD in the preceding year of inclusion for which a course of 
systemic steroids and/or antibiotics therapy was started. 
- Clinically stable during 1 month. Patients have to be free of COPD exacerbation or respiratory 
tract infection within a month prior to involvement in the study, and in this period they 
should not have received antibiotics or a course of high doses of systemic steroids defined as 
more than 10 mg of prednisone a day. 
- Informed consent. 
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Exclusion criteria 
 
- Use of antibiotics or a course of high doses of systemic steroids defined as more than 10 mg 
of prednisone a day within a month prior to involvement in the study. 
- Addition of inhalation steroids to the patient’s therapy regimen within 1 year prior to study 
inclusion. Adding inhalation steroids 1 year before trial inclusion can influence the outcome 
of exacerbation frequencies. 
- Pregnant or lactating women. 
- Allergy to macrolides. 
- Liver disease (alanine transaminase and/or aspartate transaminase levels two or more times 
the upper limit of normal). 
- Asthma, defined as episodic symptoms of airflow obstruction which is reversible with 
bronchodilators, assessed with lung function testing. 
- Bronchiectasis. A CT scan (1-mm slices) was performed in all patients to exclude 
bronchiectasis. Criteria of the BTS guideline Bronchiectasis (non-CF) are used for radiologic 
definition of bronchiectasis.30 
- Malignancy of any kind for which the subject is under treatment or is being monitored as 
part of follow-up after treatment. 
- Heart failure. A patient is excluded when having clinical signs of heart failure and a cardiac 
function defined as a left ventricular ejection fraction of less than 45% confirmed by 
echocardiography or single photon emission computed tomography (SPECT) scan. 
- Use of drugs that can adversely interact with macrolides and for which therapeutic 
monitoring cannot be undertaken, e.g. ergotamine derivatives. 
 
Intervention 
 
Subjects will be randomised to receive either azithromycin 500 mg three times a week or placebo 
during a 1-year period. During this year subjects will be followed at the outpatient department at 3, 
6, 9 and 12 months after initiating the study. During these visits the following tests will be performed 
according to the flowchart (table 1): 
- Lung function testing 
- Sputum sample collection 
- Peripheral blood collection 
- Throat swab 
- Rectal swab 
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- DS14 questionnaire for assessment of type D personality (only on day 1 and month 12) 
- Hospital Anxiety Depression Scale (HADS) 
- 12-Item Short Form Health Survey (SF-12) 
- St. George’s Respiratory Questionnaire (SGRQ). 
 
In case of exacerbation subjects have the choice to get treatment from their general practitioner or 
to visit the hospital to be seen by the investigator. Either way sputum and peripheral blood will be 
collected for immunological and microbiological investigations. Also the subjects with an 
exacerbation will be asked to complete the SF-12, HADS and SGRQ. 
 
Table 1: Overview of outpatient department visits and tests 
 
Type D personality 
 
The Type D Scale (DS14) will be administered to assess Type D personality.31 This 14-item 
questionnaire comprises two subscales, Negative Affectivity and Social Inhibition, each consisting of 
seven items. Items are answered on a 5-point Likert scale, ranging from 0 (false) to 4 (true). A 
standardised cut-off score ≥ 10 on both subscales is used to classify individuals with a Type D 
personality.32 A previous study confirmed that it is the interaction of both traits, rather than the 
single traits, that incurs an increased risk of adverse health outcomes.32 Both of the DS14 subscales of 
Negative Affectivity and Social Inhibition have good internal validity (Cronbach’s α = 0.88/0.86), are 
stable over a 3-month period (r = 0.82/0.72), and are independent of mood and health status.31 
 
Depressive and anxious symptomatology 
 
The Dutch version of the Hospital Anxiety and Depression Scale (HADS) will be used to assess 
depressive and anxious symptomatology.33,34 Both subscales consist of seven items that are 
answered on a 4-point Likert Scale, ranging from 0 to 3. A cut-off score of ≥ 8 for each subscale 
represents probable clinical levels of anxiety and depression.35 Test-retest reliabilities over a 3-week 
 Day 1 Month 3 Month 6 Month 9 Month 12 Other* 
Informed consent X      
Blood work X X X X X X 
Microbiology X X X X X X 
Lung function testing X X X X X  
Rectal swab X  X  X  
Questionnaires X X X X X X 
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period for the subscales and the total scale are good (0.86 < r < 0.91).34 The dimensional structure 
and reliability of the HADS has been shown to be stable across medical settings and age groups.34  
 
Health status 
 
The Dutch version of the Short-Form Health Survey12 (SF-12) will be administered to assess generic 
health status.36,37 This generic instrument measures overall physical and mental health status, as 
indicated by the Physical Component Scale Summary (PCS) and the Mental Component Summary 
(MCS) scores.38 According to standard scoring procedures, all scale scores will be standardised to the 
general US population (range 0–100, mean = 50, SD = 10), with higher scores indicating better 
functioning. The SF-12 has been demonstrated to be a reliable and valid instrument.37 
 
Health-related quality of life 
 
Disease-specific health-related quality of life will be measured by the total score on St. George’s 
Respiratory Questionnaire (SGRQ).39 Three component scores are calculated: symptoms, activity and 
impacts (on daily life), and a total score. Total scores range from 0 to 100, with lower scores 
indicating improvement. 
 
Study endpoints 
 
Primary study outcome 
Reduction in the number of exacerbations of COPD in the year of treatment. 
 
Secondary study outcomes 
- Measurement of lung function parameters and 6-min walking distance. 
- Assessment of presence of type D personality by DS14 questionnaire. 
- Disease-specific health-related quality of life measured by St. George’s Respiratory 
Questionnaire (SGRQ). 
- Generic health status measured by the 12-Item Short Form Health Survey (SF-12). 
- Indication of anxiety and depression by Hospital Anxiety Depression Scale (HADS). 
- Microbiology: Sputum specimens will be cultured. Polymerase chain reaction (PCR) in 
sputum and serology in serum for viral and atypical microorganisms will be performed. The 
rectal swabs will be tested for change in rectal flora as a result of maintenance azithromycin. 
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- Measurement of inflammatory markers in serum [erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), pro-adrenomedullin, (pro-ADM), interleukin-6 and cytokine profiles of 
T-helper 1, T-helper 2 and T-helper 17 cells]. 
- Decrease in percentage of clinical versus outpatient department exacerbations. 
- Difference in treatment effect between subjects with and without steroid maintenance 
therapy as hypothesis-generating secondary analysis. 
- Adverse events of treatment. Symptoms that are believed to be (possibly) related to therapy 
will be reviewed at the outpatient department. If a patient has an adverse event that is 
thought to be drug related and that does not resolve, then the patient will be withdrawn 
from the study. There will be no routine ECG screening since azithromycin (in contrast to 
erythromycin) is much less likely to be a cause of a prolonged QTc interval. 
- Length of hospital stay. 
- Time till first exacerbation. 
 
 
Sample size and statistical analysis 
 
Power calculation and number of study subjects 
This calculation starts with the assumption that the number of exacerbations follows a pure Poisson 
distribution with a mean rate of 3 per subject per year in the placebo group. A 50% reduction in this 
rate is considered to be clinically relevant. Hence, in the active treatment group the mean 
exacerbation rate is set at 1.5 per subject per year. With 33 subjects per treatment group followed 
up for 1 year, this reduction is detectable with 90% power, given a test size alpha of 0.05 (2-sided). 
However, the assumption of a pure Poisson distribution may be too strong. In fact, it is plausible that 
in this case a zero-inflated Poisson process may be present (the outcome of zero exacerbations has a 
higher probability than that following from a pure Poisson distribution). In addition there is a risk of 
overdispersion (the variance is larger than the mean). These phenomena may be expected to have a 
negative (not exactly quantifiable though) effect on the power of the study. In order to reasonably 
compensate for the risk of a too low power and for subjects dropping out within 1 year of follow-up, 
the number of subjects will be augmented by 40%, so that the sample size is set at 46 subjects per 
treatment group. 
 
Statistical analysis 
The exacerbation rate (primary efficacy outcome) will be analysed using Poisson regression, with a 
log link function and the log of the time-under-treatment as offset. The exacerbation rate ratio of 
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active relatively to placebo treatment will be the efficacy parameter of interest that will be tested for 
significance at the 5% level (2-sided). In addition a 95% confidence interval of this parameter will be 
calculated. The following baseline covariates will be entered along with treatment group: steroid 
maintenance therapy, the number of exacerbations in the year preceding randomisation, age, sex, 
smoking, and the GOLD criteria (Tiffeneau index and FEV1% of predicted). In order to generate 
hypotheses concerning the modification of the treatment effect by the steroid therapy, the 
treatment-by-steroid interaction term will be added to the model and its effect will be explored. 
When necessary, the scale parameter will be used to correct the SEs for overdispersion. Additionally, 
a zero-inflated Poisson distribution will be fitted to the data in order to test if a better fit is obtained. 
Other continuous (secondary) outcome variables with measurements at baseline, 3, 6, 9 and 12 
months will be analysed using mixed model ANOVA. The following covariates will be entered in the 
model along with treatment group: the baseline measurement of the outcome variable, age, sex, 
smoking and the GOLD criteria. When appropriate, the outcome variables will be suitably 
transformed in order to obtain normally distributed residuals. 
Time to first exacerbation will be analysed using Cox proportional hazards regression with the 
following covariates entered in the model along with treatment group: age, sex, smoking and the 
GOLD criteria. Also a Kaplan-Meier curve for time to first exacerbation per treatment group will be 
presented for illustrative purposes. 
Concerning safety, the number and type of adverse event will be compared between the two 
treatment groups using the chi-square (or Fisher’s exact) test. 
 
Randomisation 
 
All eligible subjects will be randomised using block randomisation sequences generated by computer. 
Treatment allocation numbers will be entered into individually sealed opaque envelopes. The 
envelope contains a number that is concealed to the treatment allocation. The allocation list will be 
kept in a safe in the hospital pharmacy and access is possible by a non-investigator independently. In 
the event of an emergency medical situation the individual’s randomisation code and group 
allocation could be identified. 
 
Ethical aspects 
 
The study has been approved by the ethics committee Toetsingscommissie Wetenschappelijk 
Onderzoek Rotterdam (TWOR), the ethics committee of the Amphia Hospital Breda and the Centrale 
Commissie Mensgebonden Onderzoek (CCMO). 
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The research will be explained in detail (verbally and in writing) to the patient prior to enrolment in 
the study. The explanation will include the type and method of the research, the tests to be 
performed and any potential hazards. An informed consent in writing will be obtained from each 
patient. The patient can withdraw from the study at any time, without any repercussion for the 
ongoing care. 
The study will be conducted according to the International Conference for Harmonization (ICH) 
principles of Good Clinical Practice (GCP) and the Declaration of Tokyo (2004). The investigator will 
conduct all aspects of this study in accordance with all national and regional laws of the pertinent 
regulatory authorities. 
 
Discussion 
 
Despite the clinical efficacy of long-term macrolide treatment in a number of respiratory diseases, 
until recently, only smaller studies had reported on this subject in patients with COPD. These studies 
showed conflicting results. Recently Albert et al. showed in a large randomised controlled trial that 
adding daily 250 mg azithromycin to standard therapy reduced the number of exacerbations in 
patients with COPD.23 The major concern with this study, raised in a number of comments and 
editorials, was the question about the development of antimicrobial resistance, which had almost 
doubled in that trial.40 Also the question about the working mechanism of azithromycin, whether it 
has an antimicrobial or immunomodulatory effect, was not answered in that trial. 
With the current study we investigate whether long-term therapy with macrolide antibiotics can 
prevent exacerbations in patients with an instable COPD. Additionally, our study aims to assess the 
effect of long-term use of macrolides on the development of antimicrobial resistance and on 
inflammatory parameters related to COPD. We believe this study will provide more data on the 
effects of macrolide treatment in patients in COPD and will add more knowledge on its working 
mechanisms. 
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Summary 
 
Background 
Macrolide resistance is an increasing problem; there is therefore debate about when to implement 
maintenance treatment with macrolides in patients with chronic obstructive pulmonary disease 
(COPD). We aimed to investigate whether patients with COPD who had received treatment for three 
or more exacerbations in the previous year would have a decrease in exacerbation rate when 
maintenance treatment with azithromycin was added to standard care. 
 
Methods 
We did a randomised, double-blind, placebo-controlled, single-centre trial in the Netherlands 
between May 19, 2010, and June 18, 2013. Patients (≥18 years) with a diagnosis of COPD who had 
received treatment for three or more exacerbations in the previous year were randomly assigned, via 
a computer-generated randomisation sequence with permuted block sizes of ten, to receive 500 mg 
azithromycin or placebo three times a week for 12 months. Randomisation was stratified by use of 
long-term, low-dose prednisolone (≤10 mg daily). Patients and investigators were masked to group 
allocation. The primary endpoint was rate of exacerbations of COPD in the year of treatment. 
Analysis was by intention to treat. This study is registered withClinicalTrials.gov, number 
NCT00985244. 
 
Findings  
We randomly assigned 92 patients to the azithromycin group (n=47) or the placebo group (n=45), of 
whom 41 (87%) versus 36 (80%) completed the study. We recorded 84 exacerbations in patients in 
the azithromycin group compared with 129 in those in the placebo group. The unadjusted 
exacerbation rate per patient per year was 1.94 (95% CI 1.50–2.52) for the azithromycin group and 
3.22 (2.62–3.97) for the placebo group. After adjustment, azithromycin resulted in a significant 
reduction in exacerbation rate versus placebo (0.58, 95% CI 0.42–0.79; p=0.001). Three (6%) patients 
in the azithromycin group reported serious adverse events compared with five (11%) in the placebo 
group. During follow-up, the most common adverse event was diarrhoea in the azithromycin group 
(nine [19%] patients vs one [2%] in the placebo group; p=0.015). 
 
Interpretation  
Maintenance treatment with azithromycin significantly decreased exacerbation rate compared with 
placebo and should therefore be considered for use in patients with COPD who have the frequent 
exacerbator phenotype and are refractory to standard care. 
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Introduction 
 
Acute exacerbations of chronic obstructive pulmonary disease (COPD) have important implications 
for the natural course of COPD and cause high mortality rates in patients with COPD.1 Patients with 
three or more exacerbations for which hospital admission is needed have a risk of mortality that is 
four times higher than those with no exacerbations.2 Prevention of exacerbations is therefore an 
essential strategy, not only for improvement of mortality rates, but also for improvement of health-
related quality of life3 and deceleration of further decline of lung function in patients with COPD.4 
Prevention of acute exacerbations of COPD with long-term macrolide treatment is a recent 
development and the beneficial effect of this treatment has been postulated to result from both an 
antimicrobial and an immunomodulatory effect.5 The largest study to date of this approach showed 
that long-term treatment with daily azithromycin significantly decreased the frequency of acute 
exacerbations of COPD.6 However, this study included patients with at least one exacerbation within 
the previous year and those who were receiving continuous supplemental oxygen without having 
had any exacerbation. Implementation of this strategy in clinical practice might result in an excessive 
use of macrolides in patients with COPD. However, the main risk of the increasing consumption of 
azithromycin is the induction of macrolide resistance in a large group of patients, with the additional 
risk of induction of resistance to the general population.7 To benefit maximally from macrolide 
treatment and to reduce the risk of resistance simultaneously, restrictive use of azithromycin is 
presently warranted.7 Proposals have been made to reserve long-term macrolide treatment for 
patients with two or more COPD exacerbations;7,8 however, this recommendation was not supported 
by findings from clinical studies. 
We did the COpd: infLUence of Macrolides on exacerBation freqUency in patientS (COLUMBUS) trial 
to investigate whether patients with COPD who had three or more exacerbations in the previous year 
would have a decreased rate of exacerbation when maintenance macrolide treatment was added to 
standard care. 
 
Methods 
 
Study design and participants 
The study protocol has been published elsewhere.9 We undertook this prospective, randomised, 
double-blind, placebo-controlled, single-centre trial at the Amphia Hospital (Breda, the Netherlands) 
between May 19, 2010, and June 18, 2013. Eligible patients were 18 years or older, had been 
diagnosed with COPD according to the guidelines of the Global initiative for chronic Obstructive Lung 
Disease,10 and had received treatment for three or more exacerbations of COPD in the previous year 
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for which they received steroids or antibiotic treatment. Patients had to be clinically stable and could 
not have had a COPD exacerbation or respiratory-tract infection in the month before involvement in 
the study. Exclusion criteria were a history of other clinically significant respiratory diseases (e.g., 
asthma, cystic fibrosis); presence of bronchiectasis, as assessed by CT-scan; maintenance antibiotic 
treatment; use of more than 10 mg prednisolone a day; allergy to macrolides; pregnancy or lactation 
in women; liver disease (alanine transaminase or aspartate transaminase concentrations that were 
two or more times the upper limit of normal); malignant disease of any kind for which the patient 
received treatment or was being monitored as part of follow-up after treatment; heart failure; and 
the use of drugs that could adversely interact with macrolides and for which therapeutic monitoring 
could not be undertaken. All participants provided written informed consent.  
The study was approved by independent and local ethics committees. 
 
Randomisation and masking 
An independent pharmacy randomly assigned patients (1:1), via a computer-generated 
randomisation sequence with permuted blocks of ten (five per treatment group), to receive either 
azithromycin dihydrate 500 mg (Teva Pharmachemie, Haarlem, the Netherlands) or placebo, three 
times a week (Monday, Wednesday, and Friday) for 12 months. Randomisation was stratified by use 
of long-term, low-dose prednisolone (≤10 mg daily). The randomisation list was retained by the 
clinical trials pharmacist of the Amphia Hospital. Patients were enrolled by SU, RSD, and JGJVA, and 
were automatically given the next allocated treatment by clinical trials staff at the hospital pharmacy. 
Participants and investigators were masked to treatment allocation throughout the study. After data 
collection and data cleaning were completed, and after final database lock, investigators were 
unmasked and could assess outcomes and do data analysis. 
 
Procedures 
Participants were followed up at the outpatient department at scheduled visits at months 3, 6, 9, and 
12. During these visits, we obtained data for spirometry, the 6 min walk test, white-blood-cell count, 
concentrations of C-reactive protein, mid-regional pro-adrenomedullin, erythrocyte sedimentation 
rate, interleukin-6, and cytokine profiles of T-cell subsets. Additionally, patients completed the 12-
Item Short-Form Health Survey (SF-12), the Hospital Anxiety and Depression Scale, and the St 
George’s Respiratory Questionnaire at baseline and every 3 months. The type-D scale—a 14-item 
questionnaire to assess type D personality—was completed at baseline and at 12 months. Sputum 
samples were obtained for culture at baseline and at every scheduled visit. Sputum samples were 
processed according to American Society of Microbiology guidelines.11 Sputum samples were  
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Figure 1: Trial profile 
 
additionally washed in sterile saline to avoid possible contamination from the oropharynx. We 
regarded a sputum sample as representative when more than 25 polymorphonuclear leucocytes and 
less than ten squamous cells per low-power field were identified by Gram stain. We established 
antibiotic susceptibility with breakpoints from the European Committee on Antimicrobial 
Susceptibility Testing.12 In case of an exacerbation, patients were seen and treated by the study 
investigators unless the patient chose to visit their family doctor. All exacerbations were defined 
according to Anthonisen criteria, and whether the patient needed treatment with steroids or 
antibiotics, or both.13 An exacerbation was regarded as severe when hospital admission was 
necessary, and mild when it was treated at the outpatient department by the study investigators or 
the patient’s family doctor. 
 
Outcomes 
The primary endpoint was rate of exacerbations of COPD in the year of treatment. Secondary 
outcomes were time to first exacerbation; hospital admission for acute exacerbations; change in 
proportion of exacerbations needing admission to hospital versus treatment in an outpatient 
department compared with the previous year; treatment for an acute exacerbation of COPD; forced 
expiratory volume in 1 s (FEV1) after bronchodilation; forced vital capacity after bronchodilation; 6 
min walking test; quality of life, as assessed by the SF-12 and the St George’s Respiratory 
Questionnaire; acquisition of macrolide resistant microorganisms in sputum; and adverse events.  
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Figure 2: Proportion of patients free from acute exacerbations of COPD according to study group  
 
Results of mid-regional pro-adrenomedullin, erythrocyte sedimentation rate, interleukin-6, cytokine 
profiles of T-cell subsets, the Hospital Anxiety and Depression Scale, and the type-D scale will be 
presented elsewhere.  
 
Statistical analysis 
The sample size was calculated with the assumption that the number of exacerbations followed a 
Poisson distribution with a mean rate of three exacerbations per patient per year in the placebo 
group. With 33 participants per treatment group followed up for 1 year, a 50% reduction was 
detectable with 90% power (two-sided α 0.05). The calculation was based on an exact conditional 
binomial test, allowing exact inference on the rate ratio. To account for possible zero inflation, 
overdispersion, and participants dropping out earlier than 1 year after start of the study, the sample 
size was augmented by 40%, to 46 individuals per treatment group.  
We analysed exacerbation rate with Poisson regression, with a log-link function and the log of time-
in-study as an offset variable, and with covariates of long-term, low-dose prednisolone use, number 
of exacerbations in the preceding year, age, sex, smoking, and FEV1. We corrected for overdispersion 
by multiplying the standard errors by the square root of the ratio of the Pearson χ2 value to its 
number of degrees of freedom. We included all randomly assigned patients in the intention-to-treat 
analysis; for the per-protocol analysis we included only those who completed follow-up. The 
exacerbation rate ratio of azithromycin versus placebo treatment was tested for significance at the 
5% level (two sided). Interaction between treatment and long-term, low-dose prednisolone use was 
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also examined in an exploratory analysis. Time to first exacerbation was analysed with Kaplan Meier 
survival analysis and log-rank test. To investigate the effect of treatment, with discrimination 
between occurrences of mild and severe exacerbations, we used generalised linear modelling with a  
logit-link function and a robust variance estimator to analyse the probability of hospital admission 
due to a given acute exacerbation of COPD; treatment was the only variable entered in this model. 
We did a similar analysis for the proportion of patients’ exacerbations treated with antibiotics. 
Furthermore, the effect of treatment on the difference in the proportion of exacerbations requiring 
hospital admission versus outpatient treatment between the treatment year and the previous year 
was analysed with similar generalised linear modelling, whereby the correlation between the 
hospital proportions of the previous and treatment year was accounted for through the generalised 
estimation equations method. Secondary continuous outcome variables measured at baseline and at 
months 3, 6, 9, and 12 were analysed with linear mixed modelling. In addition to treatment, the 
baseline measurement of the outcome variable of interest was included as a covariate. Missing 
values over time for lung function parameters, 6 min walking test, C-reactive protein, and white-
blood-cell count, caused by patients who withdrew before the end of the study, were appropriately 
imputed by the maximum likelihood estimation procedure used in linear mixed modelling, on the 
basis of the multivariate structure of the available measurements in time. Treatment effects were 
estimated by visit and overall across visits if the treatment-by-visit interaction was not significant 
(p>0.01). For adverse events and baseline characteristics, comparisons of parameters between 
treatment groups were calculated with a t-test if normally distributed and with a Mann-Whitney U 
test if not. We compared categorical data between the treatment groups with the exact χ2 trend or 
Fisher’s test, as appropriate. Statistical analysis was done with SPSS (version 21). 
This study is registered with ClinicalTrials.gov, number NCT00985244. 
 
Role of the funding source 
The sponsor of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data in the 
study and had final responsibility for the decision to submit for publication. 
 
Results 
 
Figure 1 shows the trial profile. We randomly assigned 92 patients to the azithromycin group (n=47) 
or the placebo group (n=45), of whom 41 (87%) versus 36 (80%) completed the study. All 92 patients 
received at least one dose of the assigned treatment (figure 1). In 91 (99%) patients bronchiectasis 
was excluded by chest CT scan. Table 1 shows baseline characteristics. We recorded 84 exacerbations 
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in patients in the azithromycin group compared with 129 in those in the placebo group (table 2). 13 
(28%) participants in the azithromycin group did not have any exacerbation compared with three 
 
 Azithromycin group 
(n=47) 
Placebo group (n=45) 
Male 22 (46·8%) 18 (40%) 
Age  64·7 (10·2) 64·9 (10·2) 
Current smoker 20 (42·6%) 9 (20%) 
Body-mass index (kg/m2) 25·9 (4·6) 26·3 (5·7) 
AECOPD in past year 
Hospitalisation due to AECOPD 
4·0 (1·2) 
1·0 (1·1)  
4·0 (1·1) 
0·7 (0·8) 
Symptoms  
- Cough 
- Sputum production 
 
28 (59·6%) 
29 (61·7%) 
 
34 (75·6%) 
32 (71·1%) 
Spirometry after bronchodilation 
- FEV1 (L) 
- FEV1 (% of predicted) 
- FVC (L) 
- FVC (% of predicted) 
- FEV1/FVC (%) 
 
1·1 (0·47) 
44·2 (19·3) 
2·9 (0·8) 
92·5 (22·2) 
38·0 (11·7) 
 
1·1 (0·43) 
45·0 (19·5) 
2·7 (0·92) 
88·9 (20·3) 
40·3 (12·4) 
GOLD stages 
- I 
- II 
- III 
- IV 
 
2 (4·3%) 
14 (29·8%) 
18 (38·3%) 
13 (27·7%) 
 
3 (6·7%) 
12 (26·7%) 
20 (44·4%) 
10 (22·2%) 
6-min walk test (m) 
6-min walk test (% of predicted) 
402 (101) 
79 (20) 
365 (136) 
74 (27) 
Medications  
- LABA 
- LAMA 
- ICS 
- SABA 
- Prednisolone  
 
45 (95·7%) 
42 (89·4%) 
42 (89·4%) 
32 (68·1%) 
11 (23·4%) 
 
41 (91·1%) 
32 (71·1%) 
43 (95·6%) 
33 (73·3%) 
9 (20·0%) 
Influenza vaccination in past year  
- Yes 
- No 
- Not registered 
 
34 (72·3%) 
5 (10·6%) 
8 (17·0%) 
 
41 (91·1%) 
1 (2·2%) 
3 (6·7%) 
SGRQ total score 
- Symptoms 
- Activity 
- Impacts 
57·4 (14·7) 
61·4 (19·1) 
77·7 (20·6) 
43·3 (15·2) 
57·6 (14·7) 
61·9 (16·4) 
75·0 (19·5) 
45·8 (17·2) 
SF-12 
- Physical component score 
- Mental component score 
 
33·9 (10·0) 
37·4 (12·7) 
 
33·5 (9·0) 
39·9 (11·4) 
CRP (mg/L)* 2 (1-180) 4 (1-42) 
Leukocytes (x109/L)* 8·1 (5·8-17·1) 8·4 (5·1-17·4) 
 
Table 1: Baseline characteristics determined on day 0 of study treatment 
Data are in n (%) or mean (SD), unless otherwise stated. AECOPD=acute exacerbations of COPD. FEV1=forced 
expiratory volume in 1 second. FVC=forced vital capacity. LABA=long-acting beta agonist. LAMA=long-acting 
muscarinic antagonist. ICS=inhalation corticosteroid. SABA=short-acting beta agonist. SGRQ=St. George’s 
Respiratory Questionnaire. SF-12=12-Item Short Form Health Survey.  *Median (range). 
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Table 2: Overview of exacerbations and hospitalisations in the year prior to the study and during follow-up 
AECOPD=acute exacerbation of COPD.  
*Azithromycin to placebo ratio of the OR of changes 0·86, 95% CI: 0·35-2·07; p=0·73. 
 
(7%) participants in the placebo group. The unadjusted exacerbation rate per patient per year was 
1.94 (95% CI 1.50–2.52) for the azithromycin group and 3.22 (2.62–3.97) for the placebo group. The 
rate ratio (RR) of azithromycin to placebo was 0.60 (95% CI 0.43–0.84; p=0.003). After adjustment for 
covariates, the analysis remained significant (azithromycin versus placebo 0.58, 0.42–0.79; p=0.001). 
Results from the unadjusted (RR 0.60, 95% CI 0.42–0.85; p=0.004) and adjusted (0.58, 0.42–0.79; 
p=0.001) per-protocol analyses were almost identical to those from the intention-to-treat analysis. 
No statistically significant difference was shown in the exacerbation rate ratio of azithromycin 
treatment to placebo between patients who did and did not already receive long-term, low-dose 
prednisolone treatment (p=0.12). 
The median time to first exacerbation was 59 days (95% CI 31–87) in the placebo group and 130 days 
(28–232) in the azithromycin group (p=0.001; figure 2). A post-hoc analysis showed that the 
probability of remaining free of exacerbations of COPD at 6 months was 0.14 (95% CI 0.04–0.24) in 
the placebo group and 0.47 (0.32–0.62) in the azithromycin group (p=0.0005). In the year of 
treatment the odds for hospital admission due to acute exacerbations of COPD did not differ 
between groups (OR 1.34, 95% CI 0.67–2.70; p=0.41). To assess whether this result was affected by 
only a few patients needing frequent admission, we did a post-hoc analysis in which no difference in 
mean time-to-first admission was noted between patients in the azithromycin group and those in the 
placebo group (282 days  vs 258 days; p=0.48). Furthermore, no difference was shown between 
groups in change of rate of hospital admission for acute exacerbations versus exacerbations treated 
in the outpatient department (table 2). We noted no difference between groups in treatment of 
severe exacerbations with additional antibiotics (OR 0.34, 95% CI 0.10–1.14; p=0.08). Mild 
exacerbations in the azithromycin group were treated significantly less often with additional 
antibiotics than were those in the placebo group (OR 0.20, 0.08–0.49; p=0.0001; table 3). During the 
 Azithromycin group (n=47) Placebo group (n=45) 
AECOPD in previous year  
- Hospitalisation, n (%) 
Odds hospitalisation/outpatient department AECOPD  
190  
48 (25·3%) 
0·34  
179  
32 (17·9%) 
0·22  
AECOPD during follow-up 
- Hospitalisation, n (%) 
Odds hospitalisation/outpatient department AECOPD  
84  
25 (29·8%) 
0·42  
129  
31 (24·0%) 
0·32  
Odds ratio of change (treatment year compared to 
previous year)*  
1.24  1.46  
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study, macrolides were prescribed to four (9%) patients in the placebo group and to none in the 
azithromycin group. 
No significant changes took place between groups in post-bronchodilator forced vital capacity, FEV1, 
and 6 min walking test from baseline to 12 months (table 4). The mean change in total score on the 
St George’s Respiratory Questionnaire differed significantly between groups at 3 months in favour of 
azithromycin (–4.2, 95% CI –8.3 to –0.1; p=0.043), but this change did not persist at 12 months (table 
4). No differences between groups were noted in mean change from baseline in the component 
scores at 12 months (table 4). However, after undertaking an estimation of the overall treatment 
effect across all visits, we recorded a significant difference in symptom score on the St George’s 
Respiratory Questionnaire between patients in the azithromycin group and those in the placebo 
group, but not in the total score or component scores of activities and impacts (table 4). The SF-12 
showed a significant difference in mean change in the mental component score at 3 months in favour 
of azithromycin (6.6, 95% CI 1.4–11.8; p=0.013), but not at 12 months (table 4). No differences were 
shown between groups in mean change in the physical component score at 3 months (data not 
shown) or 12 months (table 4). 
 
 
 
AECOPD in azithromycin 
group (n=84) 
AECOPD in placebo 
group (n=129) 
Severe exacerbation, n (%) 
- Prednisolone 
- Antibiotics 
- Prednisolone & antibiotics 
25 (29·8) 
9 (10·7) 
0 (0) 
16 (19·0) 
31 (24·0) 
5 (3·9) 
0 (0) 
26 (20·2) 
Mild exacerbation, n (%) 
- Prednisolone 
- Antibiotics 
- Prednisolone & antibiotics 
59 (70·2) 
36 (42·9) 
0 (0) 
23 (27·4) 
98 (76·0) 
25 (19·4) 
16 (12·4) 
57 (44·2) 
 
Table 3: Overview of exacerbations and given treatments during the study 
A severe exacerbation was defined as an exacerbation for which hospitalisation was necessary. A mild 
exacerbation was defined as an exacerbation treated at the outpatient department by the study investigators 
or by the general practitioner.  
Provided are percentages (%) of the number of exacerbations per treatment arm. 
AECOPD=acute exacerbations of COPD. 
 
No significant changes were recorded between groups in concentrations of C-reactive protein and 
white-blood-cell counts at 12 months compared with baseline (table 4). However, across all visits, 
significantly lower concentrations were noted in patients in the azithromycin group for both C-
reactive protein and white-blood-cell counts than in those in the placebo group (table 4). 
One or more sputum samples were obtained in 32 (68%) of the 47 patients in the azithromycin 
group, and in 32 (71%) of the 45 patients in the placebo group. At baseline, 42 sputum samples were 
obtained (22 in the azithromycin group and 20 in the placebo group), and 108 samples (51 vs 57) 
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were obtained during 1 year of follow-up (table 5). The most commonly cultured bacteria in the 
azithromycin and placebo groups at baseline were Haemophilus influenzae (n=3 vs n=2), 
Streptococcus pneumoniae (n=2 vs n=3), and Pseudomonas aeruginosa (n=2 vs n=0). During follow-
up, fewer patients in the azithromycin group had positive sputum cultures with new respiratory 
pathogens compared with those in the placebo group (n=4 vs n=12; p= 0.044; table 5). Acquisition of 
macrolide-resistant bacteria was noted in three (6%) patients in the azithromycin group compared 
with 11 (24%) patients in the placebo group (p=0.036; table 5). 
No significant differences were shown in the frequency of adverse events or serious adverse events 
between treatment groups (table4). During treatment, three (6%) patients in the azithromycin group 
had serious adverse events (table 4): two were diagnosed with lung carcinoma and a third had an 
acute coronary syndrome. Five (11%) patients in the placebo group had serious adverse events (table 
4): two developed respiratory failure due to an acute exacerbation of COPD, both of whom died; the 
third patient had a transient ischaemic attack, the fourth had an acute coronary syndrome, and the 
fifth had cholecystitis for which a cholecystectomy was done. Four (9%) patients in the azithromycin 
group and two (4%) patients in the placebo group discontinued the study because of side-effects
  
 
 
 
Table 4: Secondary outcome variables at 12 months 
 
 
 Values at 12 months  Change from baseline at 12 months Overall effect 
Azithromycin 
group (n=41) 
Placebo 
group (n=36) 
Azithromycin 
group (n=47) 
Placebo 
group (n=45) 
Difference (95% CI) 
 
P-value Difference (95% CI) P-value 
Spirometry after bronchodilation 
- FEV1 (L) 
- FEV1 (% of predicted) 
- FVC (L) 
- FVC (% of predicted) 
 
1·1 (0·47) 
43·4 (17·9) 
2·9 (0·93) 
91·0 (23·5) 
 
1·0 (0·42) 
44·2 (20·1) 
2·7 (0·79) 
88·9 (20·9) 
 
-0·03 
-1·13 
-0·04 
-0·73 
 
-0·07 
-1·80 
-0·12 
-1·21 
 
0·03 (-0·04 to 0·11) 
0·67 (-2·36 to 3·71) 
0·08 (-0·09 to 0·25) 
0·48 (-4·86 to 5·82) 
 
0·37 
0·66 
0·35 
0·86 
 
0·03 (-0·02 to 0·08) 
0·86 (-1·14 to 2·85) 
0·05 (-0·06 to 0·17) 
0·22 (-3·33 to 3·78) 
 
0·19 
0·40 
0·35 
0·90 
6-minute walk test (m) 
6-minute walk test (% of predicted) 
415 (108) 
82 (20) 
379 (121) 
76 (23) 
-1·5 
0·42 
-20·8 
-3·55 
19·3 (-17·8 to 56·5) 
3·97 (-3·66 to 11·60) 
0·31 
0·31 
8.4 (-15·2 to 31·9) 
1·40 (-3·32 to 6.13) 
0·48 
0·56 
SGRQ total score 
- Symptoms 
- Activity 
- Impacts 
56·2 (17·2) 
57·3 (18·0) 
75·5 (22·4) 
44·6 (17·8) 
57·3 (15·2) 
63·0 (14·4) 
76·1 (19·9) 
44·5 (18·3) 
-1·05 
-4·97 
-1·66 
1·12 
-0·44 
1·80 
1·37 
-1·19 
-0·61 (-5·75 to 4·53) 
-6·77 (-14·22 to 0·67) 
-3·02 (-8·72 to 2·67) 
2·31 (-4·43 to 9·05) 
0·82 
0·075 
0·30 
0·50 
-1·12 (-4·37 to 2·23) 
-5·06 (-9·64 to -0·49) 
-2·91 (-6·32 to 0·49) 
0·89 (-3·19 to 4·96) 
0·49 
0·030 
0·09 
0·67 
SF-12 
- Physical component score 
- Mental component score 
 
32·3 (10·7) 
36·8 (11·7) 
 
32·7 (10·3) 
35·9 (13·1) 
 
-0·76 
-0·04 
 
1·13 
-1·80 
 
-1·89 (-6·13 to 2·36) 
1·76 (-4·02 to 7·53) 
 
0·38 
0·55 
 
1·30 (-1·26 to 3·86) 
2·68 (-0·51 to 5·87) 
 
0·31 
0·10 
CRP (mg/L)*  2 (1-30) 3 (1-90) -20·6% -2·1% -18.9 (-50·6 to 33·2) 0·41 -27.1 (-42.3 to -8.0) 0.008 
Leukocytes (x109/L)*  8·5 (3·1-16·2) 8·9 (4·8-16·3) 2·6% 9·9% -6·7 (-17·2 to 5·1) 0·25 -8.4 (-14.2 to -2.3) 0.008 
C
hapter 4 | 68 
  
 
COLUMBUS trial | 69 
(figure 1). More patients had diarrhoea in the azithromycin group than in the placebo group 
(p=0.015; table 6). 
 
 Azithromycin 
group (n=47) 
Placebo group 
(n=45) 
Baseline 
Number of sputum samples  22 20 
Number of patients with sputum samples 22 20 
Number of patients with pathogens in sputum  7 6 
Number of patients with macrolide resistant bacteria  5 4 
Follow-up 
Number of sputum samples  51 57 
Number of patients with sputum samples 25 27 
Number of patients with newly acquired pathogens  4 12 
Number of patients with newly acquired macrolide 
resistant bacteria 
3 11 
Table 5: Overview of sputum samples per treatment group at baseline and during follow-up 
 
Discussion 
 
This study is the first to investigate macrolide treatment in patients with frequent 
exacerbations of COPD. Our findings show that treatment with azithromycin for 12 months 
decreased the rate of exacerbations and increased time to first exacerbation compared with 
placebo (panel). 
We examined a COPD population who were refractory to usual care. The proportions of 
patients who received treatment with inhaled corticosteroids (92%), long-acting beta 
agonists (LABAs) (93%), and long-acting muscarinic antagonists (LAMAs) (80%) were 
substantially higher in our study than in two prospective randomised trials investigating the 
effect of long-term macrolide treatment in patients with COPD.6,14 In Albert and colleagues’ 
study,6 inhaled corticosteroids were prescribed in 77% of the patients, LABAs in 74%, and 
LAMAs in 63%, whereas in Seemungal and colleagues’ study,14 78% of patients received 
inhaled corticosteroids, 63% received LABAs, and 33% received LAMAs. Our main inclusion 
criterion was the presence of three or more acute exacerbations of COPD in the preceding 
12 months. This criterion is in contrast with that of Albert and colleagues’ trial,6 in which 12% 
of patients did not have any exacerbations in the year before inclusion, and that of 
Seemungal and colleagues’ trial, in which 65% of patients had fewer than three 
exacerbations in the year before inclusion.14 Therefore, our main outcome cannot be directly 
compared with those from these two studies. We recorded a higher relative reduction (42%) 
in exacerbation rate than in Albert and colleagues’ trial (27%)6 and Seemungal and 
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colleagues’ trial (35%).14 Furthermore, median time to first exacerbation in the azithromycin 
(130 days) and placebo groups (59 days) in the COLUMBUS study was substantially shorter 
than that in the trials by Albert and colleagues6 (azithromycin 266 days [95% CI 227–313], 
placebo 174 days [143–215]) and Seemungal and colleagues (erythromycin 271 days, 
placebo 89 days).14 Another important finding is that 7% of patients in our control group did 
not have any exacerbation, compared with 32% of those in Albert and colleagues’ control 
group.6 This result suggests that use of a criterion of three or more exacerbations exposes 
fewer patients to redundant macrolide treatment, which consequently reduces the 
possibility of side-effects and the development of macrolide resistance. An additional 
difference between our study and that by Albert and colleagues was our use of a thrice-
weekly regimen compared with their use of daily zithromycin.6 When designing the study 
protocol, most data of long-term treatment with azithromycin were for thrice-weekly 
regimens in studies of patients with cystic fibrosis.19,20 Until now, no study has been done 
comparing a daily dosage with a thrice-weekly schedule. 
 
 
 Azithromycin group 
(n=47) 
Placebo group  
(n=45) 
Any adverse events 68  74  
Serious adverse events 3 (6·4%) 5 (11·1%) 
Most frequent adverse events* 
Gastrointestinal 
- Diarrhoea 
- Nausea or vomiting 
- Other 
 
9 (19·1%) 
3 (6·4%) 
4 (8·5%) 
 
1 (2·2%) 
2 (4·4%) 
7 (15·6%) 
Laboratory investigations 
- Creatinine increase 
- Elevated BUN 
- Hyperchloremia 
- Alkaline phosphatase increase 
- ALT increase 
- AST increase 
- γ-GT increase 
- LDH increase 
- Other  
 
7 (14·9%) 
4 (8·5%) 
6 (12·8%) 
4 (8·5%) 
5 (10·6%) 
3 (6·4%) 
6 (12·8%) 
3 (6·4%) 
9 (19·1%) 
 
3 (6·7%) 
10 (22·2%) 
5 (11·1%) 
1 (2·2%) 
4 (8·8%) 
3 (6·7%) 
1 (2·2%) 
4 (8·8%) 
17 (37·8%) 
 
Table 6: Adverse events 
Data are numbers of adverse events (%). There were no significant differences except for diarrhoea 
(p=0·015). 
*Those with an incidence of 2·5% or higher. 
BUN=blood urea nitrogen. ALT=alanine aminotransferase. AST=aspartate aminotransferase. γ-
GT=gamma-glutamyltransferase. LDH=lactate dehydrogenase. 
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Azithromycin did not improve generic and disease specific health-related quality of life, as 
assessed by SF-12 and the St George’s Respiratory Questionnaire. However, we noted a 
clinically and statistically significant average treatment effect in the symptom component 
score of the St George’s questionnaire in patients in the azithromycin group compared with 
those in the placebo group at 12 months. This improvement in symptom score might be 
attributable to the reduction in exacerbations. In a 2 year study done to assess 
exacerbations and their effect on health-related quality of life in patients with COPD, 
Miravitlles and colleagues showed that the greatest differences between frequent and 
infrequent exacerbators in the St George’s Respiratory Questionnaire were in the symptoms 
scale.21 
Macrolide treatment is an important cause of development of macrolide resistance in oral 
commensal streptococcal flora.22 We identified acquisition of macrolide-resistant bacteria in 
sputum; however, the number of positive sputum cultures was low. In line with Albert and 
colleagues’ findings, patients in the azithromycin group were less likely to become colonised 
with respiratory pathogens than were those in the placebo group.6 Furthermore, 
azithromycin significantly reduced acquisition of macrolide-resistant bacteria in sputum 
compared with placebo. In Albert and colleagues’ study, fewer patients (in absolute 
numbers) given azithromycin were colonised with macrolide-resistant respiratory pathogens 
compared with those given placebo.6,23 In our study, we could not explain this difference in 
acquisition of macrolide-resistant bacteria by additional use of macrolides during follow-up 
for any indication. 
Several randomised trials have proven the effectiveness of maintenance macrolide 
treatment for prevention of exacerbations of non-cystic-fibrosis bronchiectasis.24–26 Inclusion 
of patients with COPD with bronchiectasis in our study could have resulted in substantial 
bias because the achieved results could have been affected by patients with non-cystic-
fibrosis bronchiectasis. Therefore, we chose to exclude these patients. During the screening 
period, we excluded five of 433 patients because of bronchiectasis. This number is relatively 
low compared with that in a study by Martinez-Garcia and colleagues in which almost 58% 
of the patients with COPD had bronchiectasis.27 However, in that study, patients with COPD 
with and without previous exacerbations were included. Another notable observation in our 
study was the presence of a larger number of female than male patients with COPD. 
Additionally, in the ECLIPSE and POET studies, women had a higher tendency of exacerbating 
more frequently than did men.28–30  
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Macrolides have been extensively investigated on the basis of their postulated 
immunomodulatory effects. Evidence suggests that macrolides decrease the production of 
pro-inflammatory cytokines in response to viral infections,31 decrease the hypersecretion of 
pro-inflammatory cytokines and chemokines,32 improve alveolar macrophage phagocytosis 
function,33 and maintain integrity of the airway epithelium.34 In addition to the 
immunomodulatory effects, the decrease in airway bacterial colonisation in patients 
receiving azithromycin as shown in our study might also be associated with reduction in 
systemic inflammation.35 
Azithromycin was well tolerated in our trial. Adverse events were mostly gastrointestinal, 
with roughly a fifth of patients in the azithromycin group reporting diarrhoea, a finding 
similar to that seen in other studies of azithromycin.16,24,25 However, in Albert and 
colleagues’ study, only 5% of patients in the azithromycin group reported gastrointestinal 
complaints.6 Although, by contrast with erythromycin and clarithromycin, azithromycin does 
not change the concentrations of theophylline, we therapeutically monitored theophylline 
as described in the study protocol.9,36 We did not record theophylline concentrations greater 
than the therapeutic range. 
Our study has some limitations. First, we had small numbers of culture-positive sputum 
samples for assessment of the development of antimicrobial resistance. We did not assess 
macrolide resistance in oral commensal flora; therefore, our results might underestimate 
macrolide resistance in vivo. Second, although patients were actively asked about hearing 
loss, no standard audiometry was done. In several studies done with macrolides, no reports 
of hearing loss were made.24,25,37 At the end of our study, one patient in the placebo group 
reported hearing loss. Third, electro cardiographs were not done as standard before and 
during the study. However, apart from two patients, one in each treatment group, who had 
an acute coronary syndrome, no other cardiovascular related events or deaths were 
reported.  
In summary, our results show that long-term treatment with azithromycin could be 
recommended in patients with COPD with the frequent exacerbator phenotype who are 
refractory to standard care. However, careful monitoring of the emergence of macrolide 
resistance is warranted. 
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Abstract 
 
In this study, we investigated the occurrence of viral infections in acute COPD exacerbations 
during four seasons. 
Viral infections were detected by the use of real-time reverse transcriptase polymerase 
chain reaction on pharyngeal swabs. During a 12-month period pharyngeal swabs were 
obtained in 136 exacerbations of 63 patients. In 35 exacerbations (25,7%) a viral infection 
was detected. 
Most viral infections occurred in winter (n=14; 40,0%), followed by summer (n=9; 25,7%), 
autumn (n=6; 17,1%) and spring (n=6; 17,1%). Rhinovirus was the most frequently isolated 
virus (n=19; 51,4%), followed by respiratory syncytial virus (n=6; 16,2%), human 
metapneumovirus (n=5; 13,5%), influenza A (n=4; 10,8%), parainfluenza 4 (n=2; 5,4%) and 
parainfluenza 3 (n=1; 2,7%). 
This study showed that virus induced COPD exacerbations occur in all four seasons with a 
peak in the winter months. The distribution of rhinovirus infections however, showed a 
different pattern with most infections occurring in July.  
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Introduction 
 
Acute exacerbations of COPD (AECOPD) have important effects on the natural course of 
COPD. AECOPD are associated with morbidity and mortality and with worse health-related 
quality of life 150. It has been reported that AECOPD are predominantly caused by both 
bacterial and viral respiratory infections 21,22,151. Recent polymerase chain reaction (PCR) or 
reverse transcription (RT)-PCR based studies consistently showed a high prevalence of viral 
infections during exacerbations (22-64%) 21,26-28,152-154. Exacerbations caused by respiratory 
viruses were associated with more severe exacerbations, reflected by increased length of 
stay and decrease in lung function 25. In a recent review on the prevalence of respiratory 
viruses in AECOPD it was found that human rhinovirus (HRV) was most prevalent, followed 
by respiratory syncytial virus (RSV) and influenza virus 155. 
Epidemiological data reported a greater frequency of exacerbations in the winter months 
43,156-158. In the TORCH (TOwards a Revolution in COPD Health) study population an almost 
two-fold increase of exacerbations in the northern and southern regions during the winter 
months was observed 156. In this and in other studies, it was suggested that this increase in 
exacerbations could be caused by increased exposure to viral infections 159-161. However, 
data about seasonal variation in the prevalence of AECOPD caused by viral infections are 
lacking.  
The aim of our study was to investigate the occurrence of acute exacerbations of COPD 
caused by viral infections during four seasons.  
 
Material and methods 
 
This study was part of the COLUMBUS trial (Clinicaltrials.gov, NCT00985244), a 12-month 
prospective study performed at the Amphia Hospital, Breda, the Netherlands. Patients were 
included between May 2010 and June 2013. The study investigated azithromycin 
maintenance therapy compared to placebo in 92 patients with the frequent COPD 
exacerbator phenotype. After inclusion, patients were followed during a period of one year. 
The study protocol and the primary results have been published earlier 99,162. 
Inclusion criteria were age ≥ 18 years, a COPD diagnosis according to the guidelines of the 
Global initiative for chronic Obstructive Lung Disease, 53 and ≥ 3 AECOPD in the previous year 
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that were treated with steroids and/or antibiotics. Clinical stability during one month was 
required prior to enrolment. 
Exclusion criteria were a history of other significant respiratory diseases (e.g. asthma, cystic 
fibrosis), the presence of bronchiectasis assessed by computed tomography, heart failure, 
liver disease and malignancy of any kind for which the subject received treatment or was 
being monitored as part of follow up after treatment. 
All participants provided written informed consent. Independent and local ethics 
committees approved the study. In case of an exacerbation patients were seen and treated 
by the study investigators unless the patient chose to visit the general practitioner. All 
exacerbations were defined according to the Anthonisen criteria, requiring treatment with 
steroids and/or antibiotics 3.We obtained data for the number of exacerbations, the date of 
onset of exacerbation and the number of preceding influenza vaccinations. 
 
Collection of viral isolates 
Pharyngeal swabs were obtained during exacerbations. All pharyngeal samples were 
screened for the presence of viral respiratory pathogens by real time RT-PCR with primer 
sequences as shown in table I.  
Nucleic acids were extracted from one aliquot of 200 µL swab ‘rinse’ solution using the 
Qiagen QIA symphony automated nucleic acid extraction. Samples were tested using real-
time PCR specific for respiratory syncytial virus (A and B), human influenza virus A and B, 
parainfluenza virus 1–4, human rhinoviruses and human metapneumovirus. 
Primers, probes and PCR assay conditions used for this study have been previously reported 
in detail 163. DNA PCR was performed by using the Qiagen Qantitect Mastermix (Qiagen) and 
the RNA RT-PCR with Taqman Fast Virus-1 step mastermix (Life technologies) both according 
to manufacturer’s protocol.  
The astronomical definition of seasons for the northern hemisphere (22.5-67.5˚N) was used: 
winter (December 21-March 20), spring (March 21-June 20), summer (June 21-September 
20), autumn (September 21- December 20). 
The clinical outcomes of interest were: the number of AECOPD caused by viral infections and 
the total number of AECOPD per season.  
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Table I. Viruses, primers and primer sequences. 
 
 
RSV= respiratory syncytial virus. HRV=human rhinovirus. hMPV=human metapneumovirus 
Virus Primer Primer sequence 5′- 3′ direction 
RSV A RSVA-F1 AGATCAACTTCTGTCATCCAGCAA 
RSVA-R1 TTCTGCACATCATAATTAGGAGTATCAAT 
RSVA-1-FAM RSVA-1-FAM 
6FAM-CACCATCCAACGGAGCACAGGAGAT 
   
RSV B RSVB-F1 AAGATGCAAATCATAAATTCACAGGA 
RSVB-R1 TGATATCCAGCATCTTTAAGTATCTTTATAGTG 
RSVB-2-VIC RSVB-2-VIC 
VIC-TTCCCTTCCTAACCTGGACATAGCATATAACATACCT 
   
Influenza A >InfAF2 CTTCTRACCGAGGTCGAAACGTA 
>InfAR2 TCTTGTCTTTAGCCAYTCCATGAG 
>InfA2FAMBhq1 FAMTCAGGCCCCCTCAAAGCCGAGABhq1 
>InfA3FAMBhq1 FAMTCAGGCCCCCTCAAAGCCGAAABhq1 
   
Influenza B InfB-F2Bhq1 GRA-CAA-CAT-GAC-CAC-AAC-ACA-AAT 
InfB-R2Bhq1 CAC-TCC-ARA-ATT-CCT-GCT-TCA-AA 
InfB-2-YYBhq1 YY-CGG-GAG-CAA-CCA-ATG-CCA-CCA-TAA-ABhq1 
   
Parainfluenza 1 PIV1-F2 AAAAACTTAGGGTTAAAGACAATCCA 
PIV1-R2 GCCAGATGTRTGTCYTTCCTGCTGGT 
PIV1-3-ATTOBhq3 
(RG) 
ATTO_680-CAAACGATGGCTGAAAAAGGGABhq3 
   
Parainfluenza 2 PIV2-F2 CCATTTACCTAAGTGATGGAA 
PIV2-R2a CGTGGCATAATCTTCTTTTT 
PIV2-R2b TGTGGCATAATCTTCTTTCT 
PIV2-2-YYbhq1 YY-AATCGCAAAAGCTGTTCAGTCACBhq1 
   
Parainfluenza 3 PIV3-F2 CAGGAAGCATTGTRTCATCTGT 
PIV3-R2 ATAGTGTGTAATGCAGCTYGT 
PIV3-2-FAMbhq1 FAMACCCAGTCATAACTTACTCAACAGCAACBhq1 
   
Parainfluenza 4 PIV4-F1 CAAAYGATCCACAGCAAAGATTC 
PIV4-R1 ATGTGGCCTGTAAGGAAAGCA 
PIV4-1-Cy5bhq2 Cy5GTATCATCATCTGCCAAATCGGCAATTAAACAbhq2 
   
HRV HRV-F2a GACAGGGTGTGAAGAGCC 
HRV-F2b GACATGGTGTGAAGACCC 
HRV-F2c GACAAGGTGTGAAGAGCC 
HRV-F2d GACATGGTGTGAAGACTC 
HRV-F2e GACATGGTGTGAAGATCT 
HRV-R2 ACACGGACACCCAAAGTAGT 
HRV-2-VIC HRV-2-VIC 
VIC-TCCTCCGGCCCCTGAATGYGGCTAA 
   
hMPV hMPV-F2 CATATAAGCATGCTATATTAAAAGAGTCTC 
hMPV-R2 CCTATTTCTGCAGCATATTTGTAATCAG 
hMPV-2-FAM hMPV-2-FAM 
6FAM-TGYAATGATGAGGGTGTCACTGCGGTTG 
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Results 
 
Ninety-two patients were included of which 77 patients completed the study. Overall there 
were 213 exacerbations. A pharyngeal swab was collected in 136 AECOPD of 63 patients (1-8 
AECOPD per patient). In 35 episodes of AECOPD (25,7%) a positive pharyngeal swab was 
found with a total of 37 viruses. Multiple viruses were detected in 2 of the 35 AECOPD. The 
following viruses were isolated: HRV (n=19; 51,4%), RSV (n=6; 16,2%), human 
metapneumovirus (hMPV) (n=5; 13,5%), influenza A (n=4; 10,8%), parainfluenza 4 (n=2; 5,4) 
and parainfluenza 3 (n=1; 2,7%). 
Most viral infections occurred in winter (n=14; 40,0%), followed by summer (n=9; 25,7%), 
autumn (n=6; 17,1%) and spring (n=6; 17,1%). The results are shown in figure I.  
In the year preceding the study, 53 patients (84,1%) received influenza vaccination. All four 
patients who developed influenza A infection had been vaccinated in the year preceding the 
study. 
 
Figure I. Number of viral (n=35) and total exacerbations (n=136) in each season. 
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Discussion 
 
Our study showed that virus induced exacerbations occurred in all seasons, but were most 
frequently seen during winter months. The highest prevalence of AECOPD by all causes was 
present in the winter season as well. This seasonal pattern of COPD exacerbations has 
recently been described in the TORCH study 156.  
During all seasons viral infections were responsible for 25,7% of the AECOPD, which is in 
accordance with other studies 26-28,152,154. 
In our study HRV was the most predominant virus and was found in more than 50% of virus 
related exacerbations. It is noteworthy that no single case of HRV infection was found from 
December to February with the highest prevalence in July. Others have also demonstrated 
that HRV is the most frequently detected virus during COPD exacerbations 25,26. However, in 
contrast to our study, several studies have shown that HRV induced respiratory tract 
infections occurred most often in all seasons but not in summer 164,165. 
It is known that hMPV and RSV infections have a temporal distribution, with a variable 
activity from year to year166,167. The samples in this study were collected during 3 
consecutive years, including 3 winter periods. During the first winter period of this study no 
hMPV infections (n=5) were found. RSV infections (n=6) were equally distributed over these 
3 winter periods.  
Influenza infection can cause exacerbations in COPD 66. Since vaccination against influenza is 
proven to be protective in the prevention of influenza related airway diseases, many COPD 
patients are now receiving an influenza vaccination on yearly basis 168. In the year preceding 
the study, 53 patients (84,1%) were vaccinated for influenza virus. This could explain the low 
percentage of influenza infection (10,8%) in our study. In other studies a higher percentage 
(25%) has been found 26. 
Our study has some limitations. First, we obtained only in 136 of 213 exacerbations (63,8%) 
a pharyngeal swab for virus PCR. Second, we did not determine the presence of viral 
infections in sputum, which could have resulted in an underestimation of the presence of 
viral infections. However, the diagnostic yield in sputum and oropharyngeal samples for the 
detection of viral pathogens has shown to be equivalent 169. Third, human coronavirus has 
been acknowledged as an important cause of COPD exacerbations 170. However, because we 
only determined coronavirus in the first 35 COPD exacerbations of the study, in which 2 
patients (5.7%) turned out to be positive, we decided not implement these results in this 
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study.  
In summary, our results show that virus induced COPD exacerbations and total COPD 
exacerbations occur in all four seasons but have a peak in the winter months. The 
distribution of HRV infections however, shows a different pattern with most infections 
occurring in July.  
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Abstract 
 
Macrolides are useful in preventing COPD exacerbations. We investigated which 
characteristics of COPD patients with frequent exacerbations predicted the best response to 
maintenance treatment with azithromycin. 
This study was part of the COLUMBUS trial, a prospective randomized, double-blind, 
placebo-controlled study in 92 COPD patients with frequent exacerbations. During the 1-
year treatment period, follow-up data were collected for spirometry, mMRC scores, sputum 
cultures and blood inflammatory markers. 
In the azithromycin group a significant lower number of exacerbations per patient was 
observed in patients with the following characteristics: baseline blood eosinophil count ≥ 
2.0% (x=̄1.26), compared to an eosinophil count < 2.0% (x=̄2.50; p=0.02), GOLD stage 1-2 
(x=̄1.06), versus GOLD stage 4 (x=̄2.62; p=0.02) and GOLD group C (x=̄0.45) compared to 
group D (x=̄2.18; p<0.01). Moreover, the number of hospitalizations was significantly lower 
in patients, with a blood eosinophil count ≥ 2.0% (x=̄0.26) compared to an eosinophil count < 
2.0% (x=̄0.90; p=0.01) and in GOLD stages 1-2 (x=̄1.06) compared to stage 4 (x=̄2.62; p=0.04). 
In conclusion, azithromycin maintenance treatment is most effective in COPD patients with 
frequent exacerbations, who are either classified in GOLD stage 1-2 or GOLD C and those 
with a blood eosinophil count of ≥ 2.0%. 
 
Introduction 
 
Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and 
mortality 1. Exacerbations of COPD are associated with worsening health status and lung 
function and therefore impose a large burden on health care systems, which result in high 
cost 2,3.  
In patients experiencing COPD exacerbations macrolides have demonstrated to be 
successful in preventing exacerbations 4-6. However, long-term administration of macrolides 
can be accompanied by side-effects, such as hearing impairment 5, resting tachycardia or 
QTc time prolongation 7.  
Moreover, of greater concern is the development of bacterial resistance patterns as a result 
of chronic treatment with macrolide antibiotics 8. Goossens et al showed that antibiotic 
resistance was correlated with outpatient antibiotic use in Europe 9. This observation was 
further confirmed by Malhotra-Kumar et al, who showed that a higher consumption of 
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macrolide antibiotics resulted in higher rates of macrolide resistance 10. In order to limit 
these harmful effects, selection of patients who are most likely to benefit from long-term 
treatment with macrolides would be an advantage. Han et al showed that older patients and 
those with a milder Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) stage 
had a better treatment response to azithromycin 11. Others recommended to start 
macrolides only in patients with frequent exacerbations 8,12. Previously we showed that a 
strategy of limiting macrolide treatment to patients with three or more exacerbations a year 
resulted in a reduction of exacerbations 6.  
However, whether the population with frequent exacerbations can be stratified further to 
identify a patient population with a better response to macrolide treatment remains 
unclear. 
We therefore investigated in this study which characteristics of COPD patients with the 
frequent exacerbator phenotype showed the best treatment response to maintenance 
therapy with azithromycin. 
 
Methods 
 
This study was part of the COLUMBUS trial (Clinicaltrials.gov, NCT00985244), a prospective 
study in which 92 COPD patients who were frequent exacerbators, were followed during 12 
months at the Amphia Hospital (Breda, the Netherlands). The study protocol and the 
primary results have been previously published 13,14. Inclusion criteria were age ≥ 18 years, a 
COPD diagnosis according to the guidelines of the Global initiative for chronic Obstructive 
Lung Disease 15 and ≥ 3 exacerbations of COPD in the previous year that were treated with 
steroids and/or antibiotics. Patients were required to be clinically stable for one month prior 
to enrolment. Exclusion criteria were a history of other significant respiratory diseases (e.g. 
asthma, cystic fibrosis), the presence of bronchiectasis as assessed by computed 
tomography, heart failure, and an active malignancy. An exacerbation was defined according 
to the Anthonisen criteria, requiring treatment with steroids and/or antibiotics 16. An 
exacerbation was considered severe when hospital admission was necessary, and moderate 
when it was treated at the outpatient department by the study investigators or the patient’s 
general practitioner. All participants provided written informed consent. Independent and 
local ethics committees approved the study.  
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Procedures 
Participants were followed up at the outpatient department with scheduled visits at 3, 6, 9, 
and 12 months. During these visits, we obtained data for spirometry, mMRC-scores, white-
blood-cell count, concentrations of C-reactive protein and mid-regional pro-adrenomedullin. 
Additionally, sputum samples were obtained for culture at baseline and at every scheduled 
visit. Sputum samples were processed according to American Society of Microbiology 
guidelines 17. Sputum samples were additionally washed in sterile saline to avoid possible 
contamination from the oropharynx. We regarded a sputum sample as representative when 
more than 25 polymorphonuclear leucocytes and less than ten squamous cells per low-
power field were identified by Gram stain. Sputum was considered positive at baseline if a 
pathogenic microorganism had been cultured. We established antibiotic susceptibility with 
breakpoints from the European Committee on Antimicrobial Susceptibility Testing 18. In case 
of an exacerbation, patients were seen and treated by the study investigators unless the 
patient chose to visit their family doctor. 
We used the same cut-off values in order to dichotomize, for CRP 19 (3 mg/L) and blood 
eosinophils 20,21 (2.0% of total white blood cell count) that were used as predictors of COPD 
outcome in previous studies 22,23. 
For blood neutrophils and serum proADM we used as cut-off value the median values at 
baseline (63.3% of total white blood cell count and 0.69 nmol/L, respectively), a method that 
has been used in previous studies 24,25. 
 
Outcomes 
The total number of COPD exacerbations and the number of hospitalizations due to COPD 
exacerbations in the year of treatment. 
 
Statistical analysis 
Statistical analyses were performed using Statistical Analysis System (SAS) version 9.4 (SAS 
Institute, Cary, NC, USA). 
Subgroups were created for sex, age (<65, ≥ 65), smoking status, long acting bronchodilators 
(LABA), long acting muscarinic antagonists (LAMA), inhalationcorticosteroids (ICS) use during 
the study, prednisolone use during the study (yes, no), sputum positive at baseline, C-
reactive protein (CRP) at baseline (<3 mg/L, ≥3 mg/L), blood eosinophils at baseline (<2%, 
≥2%), blood neutrophils at baseline (<63.3%, ≥63.3%), serum proADM (<0.69 nmol/L, ≥ 0.69 
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nmol/L), GOLD stage (1-2, 3 and 4), GOLD group (C and D) and home oxygen use during the 
study. 
For all subgroups explored, descriptive statistics were calculated for the number of 
exacerbations and number of exacerbations leading to hospitalization. Within each 
treatment arm, subgroups based on phenotypes were compared using Wilcoxon’s rank sum 
test. 
 
Role of the funding source 
The sponsor of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication. 
 
Results 
 
The baseline characteristics of the 92 patients are described in table 1.  
Two subjects in the azithromycin group and one subject in the placebo arm were missing 
baseline data for COPD group (C or D) classification. There was no significant difference in 
sex, age, smoking status, use of concomitant medication, exacerbation frequency, lung 
function, GOLD stage and GOLD group classification across treatment groups at baseline. In 
22 (46.8%) patients in the azithromycin group a sputum culture on day 1 could be obtained, 
versus 20 (44.4%) patients in the placebo arm. 
 
Total number of exacerbations 
The total number of exacerbations in the year of treatment was 213, of which 84 (39%) 
exacerbations occurred in the azithromycin group versus 129 (61%) in the patients receiving 
placebo (p<0.01) (table 2).  Patients treated with azithromycin experienced a significant 
lower number of exacerbations per patient when the eosinophil count at baseline was ≥ 
2.0% (x=̄1.26), compared to those with a blood eosinophil count < 2.0% (x=̄2.50; odds ratio 
0.24 [CI] 0.06-1.02; p=0.02). The eosinophil count did not differentiate in exacerbation 
numbers in the placebo group (figure 1a). However, a blood eosinophil count of ≥ 2.0% 
predicted a significant better response after treatment with azithromycin compared to 
placebo (p<0.01), while a blood eosinophil count of < 2.0% showed no significant difference 
in response between both groups (p=0.97) (figure 1b). 
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Another significant difference in number of exacerbations in the azithromycin group was 
observed between patients classified in GOLD stage 1-2 (x=̄1.06 ± 1.29) and patients in GOLD 
stage 4 (x=̄2.62 ± 2.22; p=0.02) (figure 2). In the placebo group patients with GOLD stage 1-2 
had a significant lower number of COPD exacerbations (x=̄2.27 ± 1.28) compared to those in 
GOLD stage 3 (x=̄3.55 ± 1.99; p=0.03) (figure 2). 
Furthermore, it appeared that patients in GOLD group C had fewer exacerbations (x=̄0.45 ± 
0.69) compared to patients in GOLD group D (x=̄2.18 ± 1.85) when treated with 
azithromycin. This difference appeared to be highly significant (odds ratio 8.17 [CI] 1.80-
37.05; p<0.01). This difference in outcome was not observed in the placebo group (figure 3). 
In the placebo group the only other significant difference in the number of exacerbations 
could be observed between subjects using LAMA (x=̄3.16) versus those not using LAMA 
(x=̄2.15; odds ratio 5.64 [CI] 0.46-68.46; p<0.05) (table 2). 
 
Number of exacerbations requiring hospitalization 
We conducted subgroup analyses for the number of exacerbations with hospitalizations. The 
total number of hospitalizations during the year of treatment was 56, of which 25 (45%) 
admissions occurred in patients receiving azithromycin and 31 (55%) hospitalizations in the 
placebo group. Patients that were treated with azithromycin, who had a blood eosinophil 
count ≥ 2.0% had a significant lower number of hospitalizations (x=̄0.26 ± 0.66) than those 
with a blood eosinophil count of < 2.0% (x=̄0.90 ± 1.07; p=0.01). 
In the placebo group an eosinophil count of ≥ 2.0% (x=̄0.79 ± 1.10) showed no difference in 
number of hospitalizations compared with a blood eosinophil count < 2.0% (x=̄0.57 ± 0.87; 
p=0.47) (figure 4). 
In the azithromycin group, there was a significant difference in hospitalizations between 
stages 1-2 and 4 (p=0.04), but not between stages 1-2 and 3 (p=0.80) or between stage 3 
and 4 (p=0.06) (figure 5). In the placebo group pairwise comparison showed a significant 
difference in number of hospitalizations between GOLD stages 1-2 (x=̄0.00) and 3 (x=̄0.90 ± 
1.07; p<0.01) and also between stages 1-2 and 4 (x=̄1.30 ± 1.06; p<0.001), but not between 
stage 3 and 4 (p=0.24) (figure 5). 
For both treatment groups there was no significant difference in number of hospitalizations 
between patients classified in GOLD group C compared to patients stratified in group D 
(p=0.07) (data not shown). 
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Inflammatory markers 
The median value of pro-ADM was 0.69 nmol/L. A higher pro-ADM value was not predictive 
for the number of exacerbations during one-year follow-up. Also there was no difference 
seen in number of exacerbations when patients were treated with azithromycin or were 
receiving placebo. The same results were seen for the median value of CRP (3 mg/l) and 
median neutrophil count (63.3% of total white blood cell count). 
 
Discussion 
 
In this study we analysed which characteristics of COPD patients with frequent 
exacerbations might be predictive of a positive outcome, with regards to exacerbation, from 
maintenance treatment with azithromycin. We showed that an eosinophil count of ≥2.0% 
and classification in a lower GOLD stage (1 and 2) and in GOLD C [compared to D]) predicted 
the best treatment response to azithromycin. Additionally, we demonstrated that in patients 
in GOLD stage 1 and 2, azithromycin had a positive effect on the number of hospital 
admissions. In the placebo group there were less exacerbations in the patients with GOLD 
stage 1 or 2 when compared with those in GOLD stage 3 or 4. Eosinophil count did not have 
any effect in the placebo group. We did not observe a difference in response to azithromycin 
by sex, age, smoking, positive sputum culture, CRP, proADM, neutrophilia, other 
concomitant COPD therapy or use of home oxygen. 
Long-term use of macrolides has shown benefits in a broad range of respiratory diseases 
with airway inflammation 26-30, including COPD 4-6. However, long-acting macrolides, 
especially azithromycin, are particularly associated with increased rates of population 
bacterial macrolide resistance 31,32. The development of macrolide resistance after 
maintenance treatment has also been demonstrated on individual level 29,33. Recent studies 
in COPD patients that were treated with long-term azithromycin addressed this issue as well 
4-6. In order to prevent the widespread use of macrolides in the large population of COPD 
patients, the selection of patients who are likely to benefit the most from long-term 
macrolide treatment is desirable.  
The results from the current study suggest that the level of blood eosinophils can also be 
used as a prognostic marker as they predict the response to azithromycin therapy.  
This is a finding that has not been observed before. The role of eosinophilic inflammation 
has been described in stable COPD patients 34. In this study higher blood eosinophil counts 
were associated with an increased risk of exacerbations. Furthermore, in recent studies it 
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was found that COPD patients with higher levels of blood eosinophils had greater reduction 
in exacerbation rate during treatment with inhaled corticosteroids 21,35 or with a 
combination of ICS/LABA 36. However, a similar positive effect during treatment with 
macrolides had not been established in earlier studies. In contrast, macrolides have shown 
to be effective in chronic respiratory disorders, in which neutrophilic inflammation played a 
central role 28,37,38. 
Han et al demonstrated that treatment benefit of azithromycin is greatest in milder GOLD 
stages 11. This finding was confirmed in the present study. However, this was also been seen 
in the placebo arm. In contrast with the previous study, we didn’t observe a greater efficacy 
of azithromycin in older patients or non-smokers 11. It has to be stressed though, that both 
analyses were performed on different COPD (phenotypically distinct) populations. 
Another finding in our study was the efficacy of azithromycin observed in patients with 
GOLD group C compared to group D. It appeared that the effect of azithromycin was most 
pronounced in patients with a lower level of respiratory symptoms. The distinction between 
the categories C and D is made on the basis of symptoms, by using the modified British 
Medical Research Council dyspnea scale (mMRC), with a mMRC grade ≥ 2 indicating a high 
level of symptoms and thus inclusion in GOLD D 39. All patients in our study were categorised 
in GOLD group C and D, since only having three or more exacerbations was an a priori 
inclusion criteria.  
The main limitation of this study was that, compared to the study performed by Han et al 11, 
data were analysed from a relatively small number of patients. Therefore, we recommend 
that this analysis be repeated in larger trials. Furthermore, the current study had not 
specifically been powered for subgroup analyses.  
The great importance of this study is that these results contribute to a better selection of 
COPD patients that will benefit the most from long-term treatment with macrolides. We 
previously already showed that selection of patients with three or more exacerbations 
reduced the exacerbation rate with less patients being exposed to macrolide treatment 
unnecessarily 6. 
In conclusion, in this study we showed that patients with a blood eosinophil count of ≥ 2.0% 
have a better response to azithromycin maintenance therapy resulting in less exacerbations 
and less hospital admissions. Also patients classified in GOLD C and in GOLD stage 1 and 2 
showed a reduction in number of exacerbations after treatment with long-term 
azithromycin. 
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Table 1 Baseline characteristics of 92 patients determined on day 0 of study treatment.  
 
 Azithromycin group 
(n=47) 
Placebo group  
(n=45) 
Male 22 (46·8%) 18 (40%) 
Age (years)  64·7 (10·2) 64·9 (10·2) 
Current smoker 20 (43%) 9 (20%) 
Medication 
- LABA 
- LAMA 
- Inhaled corticosteroids 
- SABA 
- Prednisolone 
 
45 (96%) 
42 (89%) 
42 (89%) 
32 (68%) 
11 (23%) 
 
41 (91%) 
32 (71%) 
43 (96%) 
33 (73%) 
9 (20%) 
Number of AECOPD in past year (mean, SD) 
Number of hospitalisations due to AECOPD 
(mean, SD) 
4·0 (1·2) 
1·0 (1·1)  
4·0 (1·1) 
0·7 (0·8) 
Spirometry after bronchodilation (mean, SD) 
- FEV1 (L) 
- FEV1 (% of predicted) 
- FVC (L) 
- FVC (% of predicted) 
- FEV1/FVC (%) 
 
1·1 (0·47) 
44·2 (19·3) 
2·9 (0·8) 
92·5 (22·2) 
38·0 (11·7) 
 
1·1 (0·43) 
45·0 (19·5) 
2·7 (0·92) 
88·9 (20·3) 
40·3 (12·4) 
GOLD stages 
- I 
- II 
- III 
- IV 
 
2 (4·3%) 
14 (29·8%) 
18 (38·3%) 
13 (27·7%) 
 
3 (6·7%) 
12 (26·7%) 
20 (44·4%) 
10 (22·2%) 
GOLD groups 
- A 
- B 
- C 
- D 
- Unknown 
 
0 
0 
11 (23.4%) 
34 (72.3%) 
2 (4.3%) 
 
0 
0 
16 (35.6%) 
28 (62.2%) 
1 (2.2%) 
Definition of abbreviations: LABA=long-acting β-agonists; LAMA=long-acting muscarinic agents; 
SABA=short-acting β-agonists; AECOPD=acute exacerbation of chronic obstructive pulmonary disease; 
FEV1=forced expiratory volume in 1 second; FVC=forced (expiratory volume) vital capacity; 
GOLD=global initiative for chronic obstructive pulmonary disease. Data are ± standard deviation 
unless otherwise indicated.
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Table 2 Number of exacerbations in the year of treatment 
 
 
Definition of abbreviations: LABA=long-acting β-agonists; LAMA=long-acting muscarinic agents; 
SABA=short-acting β-agonists; ICS=inhalation corticosteroids; CRP=C reacting protein; 
ProADM=midregional pro adrenomedullin; nmol=nanomol/Liter; GOLD=global initiative for chronic 
obstructive pulmonary disease. Data are ± standard deviation unless otherwise indicated
 Azithromycin (n exacerbations=84) Placebo (n exacerbations=129) 
 n Mean number of exacerbations p 
Odds ratio 
(CI) n 
Mean number of 
exacerbations P Odds ratio (CI) 
Male 22 1.50 
0.55 1.04  (0.29-3.74) 
18 3.39 
0.11  
Female 25 2.04 27 2.52 
Age <65 (yrs) 24 1.71 0.59 1.17  (0.32-4.20) 
20 2.80 0.80 2.67  (0.22-31.75) Age >=65 (yrs) 23 1.87 25 2.92 
Current smoker 20 1.95 
0.93 0.82  (0.23-2.96) 
9 3.33 
0.55  
Ex-smoker 27 1.67 36 2.75 
No LABA 2 0.50 
0.26 2.75  (0.16-47.52) 
4 3.00 
0.90 6.50  (0.45-94.08) LABA 45 1.84 41 2.85 
No LAMA 5 2.20 
0.40  
13 2.15 
<0.05 5.64  (0.46-68.46) LAMA 42 1.74 32 3.16 
No ICS 5 0.60 
0.08 4.80  (0.70-32.90) 
2 1.50 
0.31 20.50  (0.91-461.50) ICS 42 1.93 43 2.93 
No Prednisolone 37 1.70 
0.23 4.32  (0.49-38.13) 
36 2.89 
0.78 0.47  (0.04-5.85) Prednisolone 10 2.10 9 2.78 
Sputum positive 7 1.43 
0.16 0.38  (0.04-3.52) 
6 3.50 
0.17 0.38  (0.02-7.40) Sputum negative 15 2.07 14 2.50 
CRP < 3 (mg/L) 26 1.62 
0.27 2.25  (0.58-8.73) 
19 2.47 
0.27 2.94  (0.25-35.06) CRP ≥ 3 (mg/L) 21 2.00 26 3.15 
Eosinophils<2,0% 22 2.50 
0.02 0.24  (0.06-1.02) 
21 2.52 
0.23 0.41  (0.03-4.91) Eosinophils ≥ 2,0% 25 1.26 24 3.17 
Neutrophils<63,3% 30 1.73 0.53 2.33  (0.54-10.05) 
16 3.00 0.79 4.00 (0.33-47.99) Neutrophils ≥ 63,3% 17 1.88 29 2.79 
ProADM<0,69 (nmol/L) 28 2.14 
0.11 0.72  (0.20-2.63) 
21 3.00 
0.65 2.30  (0.19-27.59) ProADM ≥ 0,69 (nmol/L) 19 1.26 23 2.83 
  GOLD 1-2 16 1.06 0.19 (vs 3)  15 2.27 0.03 (vs 3)  
GOLD 3 18 1.83 0.21 (vs 4)  20 3.55 0.09 (vs 4)  
GOLD 4 13 2.62 0.02 (vs 1-2)  10 2.40 0.85 (vs 1-2)  
GOLD C 11 0.45 <0.01 8.17  (1.80-37.05) 
16 2.63 0.38  
GOLD D 34 2.18 28 3.11 
No Home Oxygen 38 1.68 
0.12  
38 2.63 
0.12 0.33  (0.03-4.27) Home Oxygen 9 2.22 7 4.14 
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Figure 1a: Average number of exacerbations during treatment period per treatment group and levels of 
eosinophils in blood. 
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Figure 1b: Average number of exacerbations during treatment period per level of eosinophils in blood and 
treatment group. 
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Figure 2: Average number of exacerbations during treatment period per treatment group and GOLD stage. 
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Figure 3: Average number of exacerbations during treatment period per treatment group and ABCD GOLD 
group. 
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Figure 4: Average number of hospitalizations due to exacerbations during treatment period per treatment 
group and levels of eosinophils in blood 
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Figure 5: Average number of hospitalizations due to exacerbations during treatment period per treatment 
group and GOLD stage
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Introduction 
 
Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality 1. 
Exacerbations in COPD patients impose a large burden on health care costs and are important events 
in disease progression 2,3. 
COPD exacerbations are mainly caused by bacterial and viral infections, leading to airway 
inflammation 4,5. Macrolides have antimicrobial, anti-inflammatory and anti-viral effects, which make 
them potentially useful in reducing COPD exacerbations 6. Hence, maintenance treatment with 
macrolide antibiotics has shown to be effective in reducing exacerbations in COPD patients 7-9. 
A major concern with prolonged treatment with antibiotics is the development of bacterial 
resistance 10,11. The use of macrolides has been associated with the development of macrolide 
resistance in oral commensal streptococcal microbiota 12. However, the effect of maintenance 
treatment with macrolides on resistance in patients with COPD has given controversial results 7-9,13.  
Macrolide resistance can be caused by several mechanisms. Target modification is mediated by one 
or more rRNA erm methylases, which change a site in 23S rRNA 14. In addition, the mefA gene is 
responsible for a macrolide efflux pump system 15,16. Some of these genes are known to persist on 
mobile genetic elements, which easily facilitate the spread of these resistance genes.   
In the present study we performed a randomized control trial to determine the effect of 
azithromycin maintenance therapy on the dynamics of macrolide resistance genes in the pharyngeal 
microbiota of COPD patients. We used a targeted (PCR-based) metagenomic approach to determine 
the presence and relative abundance of specific macrolide resistance genes; ermB, ermF and mefA. 
 
Methods 
 
Study design and participants 
This study was part of the COLUMBUS trial (Clinicaltrials.gov, NCT00985244), a randomised, double-
blind, placebo-controlled trial to measure the effect of maintenance treatment with azithromycin in 
COPD patients on the exacerbation rates during a 12-month period. The study protocol and the 
primary results have been published earlier 17,18. Adult patients (≥18 years) with a diagnosis of COPD 
who had received treatment for three or more exacerbations in the previous year were randomly 
assigned to receive 500 mg azithromycin or placebo three times a week for 12 months (total of 92 
patients). Additional inclusion criteria were a COPD diagnosis according to the guidelines of the 
Global initiative for chronic Obstructive Lung Disease 19, and patients were required to be clinically 
stable during one month prior to enrolment. Exclusion criteria were a history of other significant 
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respiratory diseases (e.g. asthma, cystic fibrosis), the presence of bronchiectasis assessed by 
computed tomography, heart failure, and an active malignancy.  
Randomisation was stratified by use of long-term, low-dose prednisolone (≤10 mg daily). Patients 
and investigators were masked to group allocation. The study was approved by the Mater Human 
Research Ethics Committee and all participants provided written informed consent.  
 
Sample collection 
During the treatment period, throat samples (e-swabs) were collected at baseline, 6 months and 12 
months, as well as during each exacerbation that required admission to the hospital. E-swabs were 
stored at –80°C until molecular analysis was performed. 
 
Molecular methods 
The extraction of DNA was performed from the collected e-swabsTM (COPAN BV), using the EasyMAG 
(Biomérieux). Real-time PCR was performed to detect and quantify genes responsible for resistance 
to macrolides; ermB, ermF and mefA. Amplification of ermB was performed as described earlier 20. 
Primers to target mefA and the forward primer for ermF were adapted from earlier described studies 
21,22. A reverse primer for ermF was designed by performing an nBLAST in GenBank for the ermF gene 
sequence (NG_047826.1) and aligning all resulting sequences with >75% query coverage (identity: 
94-100%) using MAFFT (http://mafft.cbrc.jp/alignment/software/), after which a primer homologous 
to all sequences was chosen.  
The 16S ribosomal DNA was amplified as a reference gene to normalize for the amount of bacterial 
DNA in the samples, using previously described primers 23. All targets were amplified by using a MyiQ 
Single-Color Real-Time PCR Detection System (BioRad, Hercules, CA, USA) in 25-μL reactions 
containing 12.5 μL iQ SYBR Green Supermix (BioRad), 300 nM of both the respective targets forward 
and reverse primer and 5-μL template DNA. Primer sequences, amplicon sizes and PCR cycling 
conditions are displayed in Table 1. For all antibiotic resistance gene targets, specificity of the assay 
was investigated by melting curve analysis of all samples and amplicon sequencing of 10 random 
positive samples using the PCR primers and an ABI BigDye Terminator v1.1 Cycle Sequencing Kit. 
Sequencing data were obtained on an ABI 3730 DNA Analyzer (Applied Biosystems, Foster City, CA, 
USA). Efficiencies of the assays were determined to be 103.1% (16S rDNA), 99.7% (ermF) and 105.1% 
(mefA). 
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Statistical methods 
The prevalence of the macrolide genes between the treatment groups was compared using a χ2 test.  
In addition, acquisition and loss of the different resistance genes between the different treatment 
groups were compared using a χ2 test.  
A comparison of the resistance gene abundances between treatment groups was performed based 
on the samples of both month 6 and month 12. These comparisons were based on the change from 
baseline, relative to the amount of 16S DNA present, using real-time PCR. These ratios – or fold 
changes –  were calculated for ermB, ermF and mefA using the ΔΔCT method with a Pfaffl 
modification to correct for PCR efficiency as described earlier (20). This method is standard to 
measure the relative change in mRNA expression levels by using real-time PCR. Here, we measure 
the relative amount of target DNA present rather than measuring mRNA expression. The 16S rDNA 
was used as the reference gene. In order to perform paired-analysis, multiple throat samples from 
one patient have to be available in which the presence of the gene of interest was detected. Ratio’s 
log-transformed were compared between treatment arms using the Wilcoxon rank sum test. In 
addition, descriptive statistics (n, mean, median, SD) and graphical presentations were provided for 
both time points.  
Changes from baseline in relative resistance gene abundances (ratio) were evaluated between 
samples of month 6 (and month 12) and samples of baseline using the same ΔΔCT method with a 
Pfaffl modification to correct for PCR efficiency as described earlier (20). 
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Results 
 
Study population 
The COLUMBUS trial was a single centre study that took place at the Amphia Hospital (Breda, the 
Netherlands) between May 19, 2010 and June 18, 2013. 
The placebo group consisted of 47 patients and the azithromycin group of 45 patients. The baseline 
characteristics of these 92 patients are described in table 2. 
 
Prevalence of macrolide resistance genes present in pharyngeal microbiota 
At baseline throat samples were taken in 36 (77%) patients in the placebo group and in 44 (98%) 
patients in the azithromycin group. At month 6 and 12 the available samples were, 30 and 27 in 
placebo group and 34 and 32 in azithromycin group, respectively.  
At baseline, the macrolide resistance gene mefA was present in all available throat samples. After 
both placebo or azithromycin treatment, the mefA gene was still present in all available throat 
samples at 6 and 12 months.  
Before treatment, prevalence of the macrolide resistance genes ermF and ermB were respectively 
44.4% and 86.1% in the placebo group (n=36), and respectively 59.1% and 97.7% in the azithromycin 
group (n=44)  (p=0.261 ermF, p=0.085 ermB) (Table 3). After 6 and 12 months of placebo treatment, 
the ermF and ermB genes were detected in 43.3%, 80% (6 months), 48.1% and 74.1% (12 months) of 
the throat samples tested, correspondingly, with no statistical differences regarding the presence of 
resistance genes between the treatment groups.  
Regarding the azithromycin group, the prevalence of the ermF and ermB genes at 6 months was 
67.7% and 97.1% versus 68.8% and 100% at 12 months (p=n.s.). Comparison of the ermF prevalence 
between the placebo and azithromycin groups showed no significant differences at 6 and 12 months 
(p=0.05 and p=0.109). The prevalence of ermB increased significantly over time in the azithromycin 
group compared to the placebo treated group (p=0.029 6 months, p=0.002; 12 months). 
 
Loss and acquisition of macrolide-resistance in pharyngeal microbiota during and after treatment 
with placebo or azithromycin  
In the placebo group, 27 patients had throat swabs available from visits at baseline and 6 months 
while 26-paired samples were available from baseline and 12 months. For the azithromycin group, 
there were 34 paired samples (from baseline and 6 months) and 30 pairs (from baseline and 12 
months). 
The loss and acquisition of macrolide resistance genes (mefA, ermF and ermB) in pharyngeal 
microbiota before and after treatment of the paired samples is shown in table 3. During the trial, no 
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differences were detected in the presence of the mefA gene in the pharyngeal microbiota, since the 
gene was always detected in both groups.  
For the patients without the macrolide genes ermF and ermB present in their pharyngeal microbiota 
at baseline (nermF=15 and nermB=4 in placebo, nermF=16 and nermB=1 in azithromycin), no statistical 
differences were observed in the acquisition rates between the placebo and azithromycin treated 
groups (see table 4).  
However, from the patients with the macrolide genes ermF and ermB present (nermF=12 and 
nermB=23in placebo, nermF=18 and nermB=33 in azithromycin) none of the patients treated with 
azithromycin lost the ermF and ermB gene over time, while for the placebo group, 1 and 3 patients 
lost the ermF and ermB gene after 6 months, respectively. Moreover, in 5 patients in the placebo 
group, the ermB gene was lost after 12 months, therefore, the number of patients that lost the gene 
was statistically significant higher in the placebo group compared to the azithromycin group 
(p=0.012).  
In other words, this study suggests that there is no or limited increased risk for acquisition of 
macrolide resistance genes in the azithromycin group compared to the placebo group. However, 
more patients lost the macrolide resistance gene ermB in the placebo treated group compared to the 
azithromycin group.    
 
Relative gene abundances of the macrolide resistant genes during and after treatment with 
placebo or azithromycin 
A large part of the patients in both groups already had detectable levels of macrolide genes at 
baseline. This enabled us to compare the relative abundance of the genes in throat samples to 
determine the effect of the treatment on the abundance of these genes. Abundance ratios which 
were calculated with the Pfaffl method (24) were converted to log ratios compared to baseline. To 
determine the overall abundance change of a resistance gene, ratios were log-transformed and are 
depicted in figure 1. 
The relative gene abundance of mefA after 6 months of treatment was substantially higher in the 
azithromycin group compared to the placebo group (p=0.0001) (Figure 1, table 5). Moreover, After 
12 months of treatment, this difference was also statistically significant (p=0.002) (Figure 1, table 5). 
Determining the overall increase or decrease of the abundance of the ermF gene showed that this 
gene increased over time after treatment with azithromycin compared to the placebo group as well, 
which was only significant at 12 months p=0.0124 (Figure 1, table 5). With regard to the macrolide 
gene ermB, the relative gene abundance was significantly increased over time in the azithromycin 
group compared to the placebo group after 6 and 12 months of treatment (p=0.01 and p=0.001, 
respectively) (Figure 1, table 5).   
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In conclusion, determining the relative change of the abundance of each macrolide gene showed that 
all the investigated genes increased during treatment with azithromycin. This was significant for all 
genes with the exception of ermF at month 6. 
 
Discussion 
 
Within the COLUMBUS study, maintenance treatment with azithromycin significantly decreased 
exacerbation rate compared with placebo in COPD patients 9.  In this follow-up study, throat samples 
were subjected to a molecular analysis to investigate macrolide resistance. Using real-time PCR, 
quantitative levels of mefA, ermF and ermB were determined at different time-points in order to 
measure changes over time. 
During the study, only for the ermB gene, a significant difference in prevalence between the 
azithromycin group and the placebo group was measured over time. However, this difference was 
not based on an increase in prevalence over time within patients of the azithromycin group, but was 
attributed to a loss of this resistance gene within the placebo group. For the ermF and mefA gene, no 
differences were detected in the acquisition rates. However, the high prevalence of all resistance 
genes at baseline, with mefA being present in 100% of cases should be taken into consideration. 
Looking at the relative abundance of the macrolide-resistance genes over-time, a statistical increase 
of all tested genes in the azithromycin group compared to the placebo group was observed. 
Long-term treatment with macrolides might influence the microbiological profile and antibiotic 
resistance in airways. The acquisition of respiratory pathogens and macrolide resistant 
microorganisms as a result of maintenance treatment with macrolides in COPD patients has been 
addressed in three recent studies 7,9,25. It is important to note that these studies did not have the 
ability to measure quantitative differences over-time. Seemungal and colleagues found no difference 
in colonization rates with macrolide-resistant organisms between the macrolide and placebo group 
during one year of treatment 7. Only one case of erythromycin resistance was detected in the 
macrolide treated group at 12 months. In contrast with these findings, earlier analysis of our 
COLUMBUS study found fewer patients in the azithromycin group with macrolide-resistant bacteria 
in sputum samples compared to those in the placebo group 9. Albert et al however, observed an 
increase in the incidence of colonization with macrolide-resistant organisms in the azithromycin 
group compared to the placebo group 25. 
In summary, it can be stated that there is conflicting evidence about the influence of maintenance 
treatment with macrolides on the acquisition of macrolide resistant respiratory pathogens in COPD 
patients. In the current study, only a small difference in acquisition rate of macrolide resistance 
genes between patients treated with azithromycin or placebo could be demonstrated, nevertheless, 
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a statistical increase in the relative abundance of the tested genes was found. This latter finding 
suggests that maintenance therapy with azithromycin does influence the presence of macrolide 
resistance genes, which indicates towards changes in microbiological profile. 
To our knowledge this is the first randomised controlled double blind study in a COPD population, in 
which the effect of long-term treatment with macrolides on the acquisition and relative abundance 
of macrolide resistance genes using a targeted metagenomic approach has been evaluated. 
However, this study has some limitations. Unfortunately, throat samples were not obtained from all 
patients at regular visits. Furthermore, throat samples were not cultured in order to assess the 
changes in the microbiological profile and resistance patterns. Finally, in this study we focused on 
three genes, which are involved in macrolide resistance. It is known that more genes are involved in 
this process 26,27. 
The consequences of this study for daily practice are unclear. The clinical benefit of macrolide 
maintenance therapy in COPD patients with frequent exacerbations has been demonstrated 
repeatedly 7,9,25. In the most recent update of the GOLD guidelines it is recommended to consider the 
addition of a macrolide in COPD patients treated with long-acting beta2 agonists/long-acting 
muscarinic antagonists/inhalation corticosteroids combination, who still have exacerbations 28. This 
recommendation is accompanied by the advice that the possibility of developing resistant organisms 
should be taken into consideration in the decision making. 
As indicated, at the start of the study the prevalence of macrolide-resistance genes were already high 
in throat samples. This may be the result of historical exposure to (macrolide) antibiotics in this 
specific study population, since only COPD patients with a minimum of three exacerbations in the 
previous year, have been included in this study. This could be an argument to consider macrolide 
maintenance treatment only in this specific category of COPD patients. However, this high 
prevalence has also been observed in a healthy travel population, as shown in the study of von 
Wintersdorff et al., with an ermB gene presence in 99.2 % in fecal samples 20. 
Future research should focus on the changes of the microbiological profile and macrolide resistance 
patterns in pharyngeal microbiota, sputum and fecal microbiota, during long-term treatment with 
macrolides. 
In conclusion, this study showed that the acquisition rate of macrolide resistance genes in COPD 
patients treated with azithromycin maintenance therapy was limited, but the relative abundance of 
macrolide resistance genes increased significantly over time compared to placebo. The clinical 
implications of these findings are unclear and we consider the benefits for this specific group of 
patients to outweigh the risks of antimicrobial resistance. Nevertheless, it is recommended to 
monitor the development of resistance carefully when treating patients for prolonged periods with 
antibiotics.  
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Table 1. PCR conditions and primer sequences 
Primer 
Sequence 
5’ - 3’ 
Amplicon 
size (bp) 
Cycling conditions 
16SrDNA_F CCTACGGGNGGCWGCAG 465 1x 95°C, 3’ 
16SrDNA_R GACTACHVGGGTATCTAATCC  35x 95°C, 15”; 55°C, 20”; 72°C, 30” 
ermB_F AAGGGCATTTAACGACGAAACTG 438 1x 95°C 3’ 
ermB_R ATTTATCTGGAACATCTGTGGTATG  40x 95°C 15”, 60°C 20", 72°C 30" 
ermF_F CGACACAGCTTTGGTTGAAC 120 1x 95°C 3'  
ermF_R TTTGACACCACTTTGAAAGGAAA  40x 95°C 15", 58°C 20", 72°C 30" 
mefA CCTGCAAATGGCGATTATTT  199 1x 95°C 3'  
mefA AATAGCAAGCACTGCACCAG   40x 95°C 15", 58°C 20", 72°C 30" 
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Table 2. Baseline characteristics.  
 Azithromycin group 
(n=47) 
Placebo group  
(n=45) 
Male 22 (46·8%) 18 (40%) 
Age (years)  64·7 (10·2) 64·9 (10·2) 
Current smoker 20 (43%) 9 (20%) 
AECOPD in past year 
Hospitalisation due to AECOPD 
4·0 (1·2) 
1·0 (1·1)  
4·0 (1·1) 
0·7 (0·8) 
Spirometry after bronchodilation 
- FEV1 (L) 
- FEV1 (% of predicted) 
- FVC (L) 
- FVC (% of predicted) 
- FEV1/FVC (%) 
 
1·1 (0·47) 
44·2 (19·3) 
2·9 (0·8) 
92·5 (22·2) 
38·0 (11·7) 
 
1·1 (0·43) 
45·0 (19·5) 
2·7 (0·92) 
88·9 (20·3) 
40·3 (12·4) 
 
GOLD stages 
- I 
- II 
- III 
- IV 
 
2 (4·3%) 
14 (29·8%) 
18 (38·3%) 
13 (27·7%) 
 
3 (6·7%) 
12 (26·7%) 
20 (44·4%) 
10 (22·2%) 
 
Data are in n (%) or mean (SD), unless otherwise stated. AECOPD=acute exacerbations of COPD. FEV1=forced expiratory 
volume in 1 second. FVC=forced vital capacity. GOLD=Global Initiative for Chronic Obstructive Pulmonary Disease. 
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Table 3. Prevalence of ermF and ermB macrolide resistance genes over time 
 ermF 
% (pos/all samples) 
ermB 
% (pos/all samples) 
Prevalence Placebo Azithromycin P value Placebo Azithromycin P value 
Baseline 44,4 (16/36) 59,1 (26/44) 0.261 86,1 (31/36) 97,7 (43/44) 0.085 
M6 43,3 (13/30) 67,6 (23/34) 0.050 80,0 (24/30) 97,1 (33/34) 0.029* 
M12 48,1 (13/27) 68,8 (22/32) 0.109 74,1 (20/27) 100,0 (32/32) 0.002* 
 
* Prevalence of ermB is statistically significant in the Azithromycin group at M6 and M12 compared to the 
Placebo group (Chi-square, Pearson corrected)  
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Table 4. Macrolide-resistant genes presence in pharyngeal microbiota before and after treatment 
in both groups 
    Placebo Azithromycin 
Baseline* M6* mefA ermF ermB mefA ermF ermB 
neg neg - 14 2 - 11 1 
pos - 1 2 - 5 - 
pos neg - 1 3 - - - 
pos 27 11 20 34 18 33 
Baseline* M12*       
neg neg - 12 1 - 8 - 
pos - 2 2 - 5 - 
pos neg - - 5** - - - 
pos 26 12 18 30 17 30 
 
*Throat sample at baseline, 6 and 12 months after placebo or azithromycin treatment 
**Loss of ermB gene in the placebo group after 12 months is statistically significant compared to the 
Azithromycin group (p=0.012, Chi-square, Pearson corrected) 
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Table 5. Comparison of mean logs ratios of the different macrolide–resistant genes before, during 
and after treatment 
  Placebo Azithromycin  
  Mean* SD Mean SD P value** 
mefA M6 -0.22 (n=27) 1.00 0.51 (n=34) 0.47 0.0001 
M12 -0.39 (n=26) 1.21 0.33 (n=30) 0.68 0.002 
ermF M6 -0.14 (n=11) 1.35 0.86 (n=18) 0.99 0.0687 
 M12 0.15 (n=12) 0.94 1.04 (n=17) 0.80 0.0124 
ermB M6 -0.32 (n=20) 1.48 0.69 (n=33) 0.93 0.0116 
 M12 -0.42 (n=18) 1.33 0.89 (n=30) 1.05 0.0013 
*mean of the log gene abundance ratio compared to baseline 
**p values for comparison of mean abundance at either 6 or 12 months and baseline, by Wilcoxon ranked sum 
test. 
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Figure 1. Relative changes in gene abundance at 6 and 12 months after treatment with placebo or 
azithromycin.  
 
Changes related to baseline gene abundance of mefA (A, B), ermF (C, D) and ermB (E, F) at 6 and 12 months are shown. 
Results are visualized in box-plots with median and 10th and 90th percentiles (dots show outliers). The dotted line shows the 
zero line. Mean logs ratio and statistics are shown in table 5. 
 
  
  
Molecular mechanisms modulating macrolide resistance | 123 
References 
 
1. Suissa S, Dell'Aniello S, Ernst P. 2012. Long-term natural history of chronic obstructive 
pulmonary disease: severe exacerbations and mortality. Thorax 67:957-963. 
2. Miravitlles M, Murio C, Guerrero T, Gisbert R. 2002. Pharmacoeconomic evaluation of acute 
exacerbations of chronic bronchitis and COPD. Chest 121:1449-1455. 
3. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. 2002. Relationship between 
exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. 
Thorax 57:847-852. 
4. Rohde G, Borg I, Wiethege A, Kauth M, Jerzinowski S, An Duong Dinh T, Bauer TT, Bufe A, 
Schultze-Werninghaus G. 2008. Inflammatory response in acute viral exacerbations of COPD. 
Infection 36:427-433. 
5. Sethi S, Murphy TF. 2008. Infection in the pathogenesis and course of chronic obstructive 
pulmonary disease. N Engl J Med 359:2355-2365. 
6. Yamaya M, Azuma A, Takizawa H, Kadota J, Tamaoki J, Kudoh S. 2012. Macrolide effects on 
the prevention of COPD exacerbations. Eur Respir J 40:485-494. 
7. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. 2008. Long-
term erythromycin therapy is associated with decreased chronic obstructive pulmonary 
disease exacerbations. Am J Respir Crit Care Med 178:1139-1147. 
8. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr., Criner GJ, Curtis JL, Dransfield MT, 
Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner 
DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, 
Anthonisen NR, Network CCR. 2011. Azithromycin for prevention of exacerbations of COPD. 
N Engl J Med 365:689-698. 
9. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, Van't Veer NE, Ermens AA, Pelle AJ, 
Hoogsteden HC, Aerts JG, van der Eerden MM. 2014. Azithromycin maintenance treatment in 
patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): 
a randomised, double-blind, placebo-controlled trial. The lancet. Respiratory medicine 2:361-
368. 
10. Serisier DJ. 2013. Risks of population antimicrobial resistance associated with chronic 
macrolide use for inflammatory airway diseases. The lancet. Respiratory medicine 1:262-274. 
11. Li H, Liu DH, Chen LL, Zhao Q, Yu YZ, Ding JJ, Miao LY, Xiao YL, Cai HR, Zhang DP, Guo YB, Xie 
CM. 2014. Meta-analysis of the adverse effects of long-term azithromycin use in patients 
with chronic lung diseases. Antimicrob Agents Chemother 58:511-517. 
12. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. 2007. Effect of 
azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant 
streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. 
Lancet 369:482-490. 
13. Hahn DL. 2011. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 
365:2236-2236; author reply 2236-2237. 
14. Leclercq R, Courvalin P. 1991. Bacterial resistance to macrolide, lincosamide, and 
streptogramin antibiotics by target modification. Antimicrob Agents Chemother 35:1267-
1272. 
  
Chapter 7 | 124 
15. Clancy J, Petitpas J, Dib-Hajj F, Yuan W, Cronan M, Kamath AV, Bergeron J, Retsema JA. 1996. 
Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, 
from Streptococcus pyogenes. Mol Microbiol 22:867-879. 
16. Tait-Kamradt A, Clancy J, Cronan M, Dib-Hajj F, Wondrack L, Yuan W, Sutcliffe J. 1997. mefE is 
necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. 
Antimicrob Agents Chemother 41:2251-2255. 
17. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, Van't Veer NE, Ermens AA, Pelle AJ, 
Hoogsteden HC, Aerts JG, van der Eerden MM. 2014. Azithromycin maintenance treatment in 
patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): 
a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 
18. Uzun S, Djamin RS, Kluytmans J, Van't Veer NE, Ermens AA, Pelle AJ, Mulder P, van der 
Eerden MM, Aerts J. 2012. Influence of macrolide maintenance therapy and bacterial 
colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study 
protocol for a randomised controlled trial. Trials 13:82. 
19. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-
Roisin R, van Weel C, Zielinski J. 2007. Global strategy for the diagnosis, management, and 
prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir 
Crit Care Med 176:532-555. 
20. von Wintersdorff CJ, Penders J, Stobberingh EE, Oude Lashof AM, Hoebe CJ, Savelkoul PH, 
Wolffs PF. 2014. High rates of antimicrobial drug resistance gene acquisition after 
international travel, The Netherlands. Emerging infectious diseases 20:649-657. 
21. Szczepanowski R, Linke B, Krahn I, Gartemann KH, Gutzkow T, Eichler W, Puhler A, Schluter A. 
2009. Detection of 140 clinically relevant antibiotic-resistance genes in the plasmid 
metagenome of wastewater treatment plant bacteria showing reduced susceptibility to 
selected antibiotics. Microbiology 155:2306-2319. 
22. Chen J, Yu Z, Michel FC, Jr., Wittum T, Morrison M. 2007. Development and application of 
real-time PCR assays for quantification of erm genes conferring resistance to macrolides-
lincosamides-streptogramin B in livestock manure and manure management systems. Appl 
Environ Microbiol 73:4407-4416. 
23. Klindworth A, Pruesse E, Schweer T, Peplies J, Quast C, Horn M, Glockner FO. 2013. 
Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation 
sequencing-based diversity studies. Nucleic acids research 41:e1. 
24. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. 
Nucleic acids research 29:e45. 
25. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr., Criner GJ, Curtis JL, Dransfield MT, 
Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner 
DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, 
Anthonisen NR. 2011. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 
365:689-698. 
26. Leclercq R. 2002. Mechanisms of resistance to macrolides and lincosamides: nature of the 
resistance elements and their clinical implications. Clin Infect Dis 34:482-492. 
27. Varaldo PE, Montanari MP, Giovanetti E. 2009. Genetic elements responsible for 
erythromycin resistance in streptococci. Antimicrob Agents Chemother 53:343-353. 
28. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, 
Decramer M, Fabbri LM, Frith P, Halpin DM, Lopez Varela MV, Nishimura M, Roche N, 
  
Molecular mechanisms modulating macrolide resistance | 125 
Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. 2017. Global 
Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 
2017 Report: GOLD Executive Summary. Eur Respir J. 
 
  
  
  
  
Chapter 8 
 
 
Summary and future perspectives 
 
 
  
  
Chapter 8 | 128 
Summary 
 
At the start of the study it was clear that exacerbations of COPD have a major impact on lung 
function, morbidity and mortality. Therefore it is important to reduce exacerbations, especially in 
those COPD patients who are prone to recurrent exacerbations. 
Despite several interventions, that have proven to be effective in reducing exacerbations, there is 
still an unmet need to a further reduction. 
Several studies have demonstrated the causative role of bacteria in COPD exacerbations. Hence, 
long-term treatment with antibiotics could be useful. Besides antimicrobial effects macrolide 
antibiotics have anti-inflammatory effects as well. Macrolides have been successfully used as 
maintenance treatment in several chronic inflammatory pulmonary diseases. 
Chapter 1 provides a comprehensive overview of different aspects of acute exacerbations of COPD 
and the aim of this study. 
In chapter 2 the current understanding of the value of maintenance therapy with macrolides to 
reduce COPD exacerbations, according to recent studies is described. Several recent studies show 
that a significant reduction of exacerbation frequency in COPD patients can be achieved with long-
term macrolide therapy. Based on the review of the literature we decided, in our COLUMBUS study 
to evaluate long-term macrolide therapy in the subgroup of COPD patients with at least three 
exacerbations in the previous year. Azithromycin was chosen based on the fact that it has fewer 
adverse effects compared with other macrolides.  The study protocol is described in chapter 3. We 
demonstrated that a regimen of azithromycin treatment 500 mg three times a week during one year 
compared to placebo, leads to a larger reduction in exacerbation frequency in COPD patients with a 
minimum of three exacerbations in the previous year (chapter 4). Since it is known that besides 
bacterial infections, viral infections also play an important role in COPD exacerbations we 
investigated which viruses could be detected during the treatment period (chapter 5). We found a 
viral infection in a quarter of exacerbations. It was found that human rhinovirus (HRV) was most 
prevalent, followed by respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).  It 
appeared that most viral infections occurred in winter, followed by summer, autumn and spring. A 
different pattern was observed for HRV with a peak in July. 
In chapter 6 we investigated which characteristics of COPD patients with frequent exacerbations 
predicted the best response to maintenance treatment with azithromycin. Long-term treatment with 
azithromycin resulted in a significant lower number of exacerbations in patients with the following 
characteristics: baseline blood eosinophil count ≥ 2.0% (compared to an eosinophil count < 2.0%), 
GOLD stage 1-2 (versus GOLD stage 4) and GOLD group C (compared to group D). Also, the number of 
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hospitalizations was significantly lower in patients with a blood eosinophil count ≥ 2.0% (compared 
to an eosinophil count < 2.0%) and in GOLD stages 1-2 (compared to stage 4). 
Since the development of bacterial resistance during prolonged treatment with macrolide antibiotics 
is a major concern, we determined the effect of azithromycin maintenance therapy on the dynamics 
of macrolide resistance genes in the pharyngeal microbiota of the COPD patients in the COLUMBUS 
trial. In chapter 7 we showed that the acquisition of macrolide resistance genes was limited but the 
relative abundance of macrolide resistance genes increased significantly over time compared to 
placebo. However the clinical implications of these results are unclear, it is therefore recommended 
to monitor the development of resistance carefully when treating patients for prolonged periods 
with antibiotics. 
 
Future perspectives 
 
It has been shown that long-term treatment with macrolides is effective in reducing exacerbations 
and the severity of exacerbations in COPD patients. However, in view of the large population of 
COPD patients and potential spread of macrolide use, patient selection is very important. This 
intervention should only be considered in optimally treated patients.  Non-pharmacological 
interventions such as influenza vaccination and pulmonary rehabilitation should be deployed. Finally, 
patients should be treated with maximum pharmacological therapy (ICS, LABA, LAMA) in order to 
reduce exacerbation frequency. If these measures do not result in reduction of exacerbation 
frequency, long-term treatment with azithromycin should be used. 
In our study we demonstrated that, in comparison with other studies, the greatest benefit of 
treatment with macrolides could be achieved in COPD patients with frequent exacerbations in the 
past year. We showed that a criterion of three or more exacerbations in the previous year, results in 
a higher relative reduction in exacerbation rate.  
There is no consensus about the optimal duration of therapy. Todate, in all recent studies patients 
received one-year treatment with macrolides. It is not clear if a shorter period of treatment leads to 
equal results or perhaps a prolonged treatment to an even higher reduction in exacerbation 
frequency. Also, periodic treatment during winter season could be considered. This should be 
investigated in future research. 
It is also unknown if the reduction in exacerbation rate persists in patients after prolonged treatment 
with long-term therapy. And if not, whether intermittent treatment leads to a more persistent 
reduction in exacerbation frequency. 
Based on recent studies, azithromycin seems to be the drug of choice due to its more favorable side 
effects profile. 
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However, the ideal dosage has not been determined. In our study we used the lowest cumulative 
dosage/year that has been used so far (78 g), with a regimen of 500 mg three times a week. Perhaps 
similar results can be achieved with a schedule of 250 mg three times a week. 
We showed that maintenance therapy is most effective in patients in GOLD stages I-II and C and in 
patients with blood eosinophils above 2.0%. Prospective randomized controlled studies using these 
parameters should be performed in order to confirm these findings. 
The exact working mechanism of macrolides, which leads to exacerbation reduction in susceptible 
COPD patients, is still under debate. In order to evaluate the anti-bacterial and anti-viral effects of 
macrolides in relation to reduction of exacerbations, new long-term studies with extensive 
assessment of airway colonisation, bronchial cultures of bacteria and PCR based viral detection 
techniques during exacerbations should be performed. The influence of anti-inflammatory effects of 
macrolides should be assessed by measuring the change in profile of inflammatory mediators 
(including cytokines) in sputum and serum during treatment and the relationship with exacerbation 
frequency. The effects of long-term use of non-antibiotic macrolides in COPD patients with frequent 
exacerbations could provide a clear answer to this question. 
A major concern remains the development of macrolide resistance during long-term treatment. 
Extensive surveillance cultures with measurement of resistance patterns of bacteria in the 
nasopharynx and intestines should be deployed in order to monitor the development of resistance.                                                                         
In the current study we assessed the development of macrolide resistance genes in pharyngeal flora. 
Since the gut microbiota has the largest number of bacteria, the effect of long-term macrolide use 
can be large. In a future study the development of these genes in intestinal flora should be assessed. 
Finally the changes in the microbial flora of nasopharynx and intestines during long-term treatment 
with macrolides should be assessed. New techniques such as IS-PRO or metagenomic sequencing, 
which determine bacteria without culture, could be used.  Consequently, long-term effects of 
antibiotic therapy can be observed in detail, thereby enabling a better judgement of risks and 
benefits. 
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Samenvatting 
 
Bij aanvang van de studie was reeds duidelijk dat COPD exacerbaties een grote impact hebben op 
longfunctie, morbiditeit en mortaliteit. Het beleid bij COPD patiënten moet er derhalve op gericht 
zijn om exacerbaties te verminderen, met name bij patiënten die frequent exacerbaties doormaken. 
Ondanks diverse bewezen effectieve interventies, is er nog steeds een behoefte aan interventies die 
de exacerbatiefrequentie verder kunnen reduceren. 
Diverse studies hebben de rol van bacteriën als oorzaak van COPD exacerbaties aangetoond. Hieruit 
kan worden opgemaakt dat onderhoudsbehandeling met antibiotica zinvol zou kunnen zijn. 
Naast antimicrobiële effecten, hebben macrolide antibiotica ook anti-inflammatoire eigenschappen. 
Macroliden zijn succesvol gebruikt als onderhoudsbehandeling bij diverse chronische inflammatoire 
longaandoeningen. 
Hoofdstuk 1 geeft een uitvoerig overzicht van verschillende aspecten die bij acute COPD exacerbaties 
van belang zijn. 
In hoofdstuk 2 wordt de huidige stand van zaken van onderhoudsbehandeling met macroliden 
teneinde COPD exacerbaties te reduceren op basis van recente studies, beschreven. In diverse 
recente onderzoeken wordt aangetoond dat door middel van onderhoudsbehandeling met 
macroliden een significante reductie van de exacerbatiefrequentie kan worden bereikt. In onze 
COLUMBUS studie besloten wij om onderhoudsbehandeling met macroliden te onderzoeken in de 
specifieke subgroup van COPD patiënten met tenminste drie exacerbaties in het voorafgaande jaar. 
Er is gekozen voor azithromycine, aangezien dit middel minder bijwerkingen heeft dan andere 
macroliden. Het studie protocol wordt beschreven in hoofdstuk 3. In dit onderzoek hebben we 
aangetoond dat een schema met azitromycine 500 mg drie maal per week gedurende een jaar, leidt 
tot een grotere reductie van de exacerbatiefrequentie in vergelijking met placebo, bij COPD 
patiënten met tenminste drie exacerbaties in het voorafgaande jaar (hoofdstuk 4). Aangezien bekend 
is dat, naast bacteriële infecties, virale infecties een belangrijke rol spelen als oorzaak van COPD 
exacerbaties, is onderzocht welke virussen gedetecteerd konden worden tijdens de behandelperiode 
(hoofdstuk 5). Tevens werd de verdeling over de seizoenen onderzocht. Een virale infectie werd in 
een kwart van de exacerbaties vastgesteld. Humaan rhinovirus (HRV) werd het meest frequent 
gevonden, gevolgd door respiratoir syncytieel virus (RSV) en humaan metapneumovirus (hMPV). Ook 
werd vastgesteld dat de meeste virale infecties in de winter plaatsvinden, gevolgd door zomer, herfst 
en voorjaar. Een afwijkend patroon werd gezien bij HRV, met een piek in juli.  
In hoofdstuk 6 onderzochten wij welke eigenschappen van COPD patiënten met frequente 
exacerbaties het best de respons op onderhoudsbehandeling met macroliden konden voorspellen. 
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Het bleek dat onderhoudsbehandeling met azitromycine tot een significant lager aantal exacerbaties 
leiden in patiënten met de volgende karakteristieken: uitgangs bloed eosinofielen getal ≥ 2.0% 
(vergeleken met een eosinofielen getal < 2.0%), GOLD stadium 1-2 (versus GOLD stadium 4) en GOLD 
groep C (vergeleken met groep D). Ook het aantal opnames was significant lager bij patiënten met 
een bloed eosinofielen getal ≥ 2.0% (vergeleken met een eosinofielen getal < 2.0%) en bij hen in 
GOLD stadium 1-2 (vergeleken met GOLD stadium 4). 
Aangezien de mogelijke ontwikkeling van bacteriële resistentie tijdens langdurige behandeling met 
macrolide antibiotica een groot punt van zorg is, onderzochten wij het effect van deze behandeling 
op het verloop van macrolide resistentie genen in de pharyngeale microbiële flora van de COPD 
patiënten in de COLUMBUS trial. 
In hoofdstuk 7 hebben we laten zien dat de acquisitie van macrolide resistentie genen beperkt was 
tijdens onderhoudsbehandeling, maar dat het relatieve overschot van deze genen een significante 
toename liet zien, vergeleken met placebo. Alhoewel de klinische implicaties van deze resultaten niet 
duidelijk zijn, is het aan te raden om het optreden van resistentie zorgvuldig te monitoren bij 
patiënten die langdurig met antibiotica worden behandeld. 
 
Toekomstige ontwikkelingen 
 
Het is aangetoond dat onderhoudsbehandeling met macroliden effectief is in het reduceren van het 
aantal en de ernst van de exacerbaties. Gelet op de grote populatie van COPD patiënten en 
dientengevolge de effecten van wijdverspreid gebruik van macroliden , is patiënt selectie echter 
belangrijk. Deze behandeling moet pas overwogen worden bij patiënten, die optimaal worden 
behandeld. Non-farmacologische maatregelen die de exacerbatiefrequentie gunstig kunnen 
beïnvloeden, zoals influenza vaccinatie en longrevalidatie moeten eerst zijn toegepast. Tot slot 
moeten patiënten maximaal farmacologisch zijn behandeld met ICS, LABA en LAMA, teneinde de 
exacerbatiefrequentie te minimaliseren. 
In ons onderzoek hebben we laten zien dat, in vergelijking met andere studies, het grootste 
behandeleffect bereikt kan worden bij de groep COPD patiënten met frequente exacerbaties 
(tenminste drie) in het voorafgaande jaar. We hebben aangetoond dat dit criterium resulteert in een 
hogere relatieve reductie in exacerbatiefrequentie. 
Er bestaat geen consensus over de optimale duur van de behandeling. Tot op heden hebben alle 
patiënten in de meest recente studies een onderhoudsbehandeling van een jaar gekregen. Het is niet 
duidelijk of een kortere behandelduur tot gelijkwaardige resultaten leidt of een langere duur wellicht 
tot een nog hogere reductie in exacerbatiefrequentie. Ook periodieke behandeling tijdens de 
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wintermaanden zou zinvol kunnen zijn. Dit zou in vervolgonderzoek onderzocht dienen te worden. 
Het is ook niet bekend of het effect van de afname in exacerbaties aanhoudt na de 
onderhoudsbehandeling met macroliden. En, als dat niet het geval is, of intermitterende behandeling 
tot een blijvende reductie leidt. 
Op basis van recente studies lijkt azitromycine het aangewezen middel te zijn voor 
onderhoudsbehandeling, op basis van een gunstiger bijwerkingen profiel. De ideale dosis is echter 
nog niet vastgesteld. In het huidige onderzoek werd in vergelijking met andere onderzoeken de 
laagste cumulatieve jaardosis ( 78 g) gebruikt, met een schema van 500 mg driemaal per week. 
Wellicht kunnen vergelijkbare resultaten worden bereikt met een schema van 250 mg driemaal per 
week. 
We hebben aanwijzingen gevonden dat onderhoudsbehandeling het meest effectief is bij patiënten 
in GOLD stadia 1-2 en C en bij patiënten met bloed eosinofielen ≥ 2.0%. Deze bevindingen zouden 
bevestigd moet worden in prospectief gerandomiseerd gecontroleerd onderzoek. 
Op basis van welk werkingsmechanisme van macroliden exacerbatiereductie in COPD patiënten 
wordt bereikt is nog niet duidelijk. Nieuwe studies bij COPD patiënten zijn noodzakelijk waarbij 
geëvalueerd wordt of anti-bacteriële en anti-virale effecten van macroliden gerelateerd kunnen 
worden aan de exacerbatiereductie , door middel van uitgebreide assessment van 
luchtwegkolonisatie, bronchiale kweken van bacteriën en virus detectie technieken op PCR basis 
gedurende exacerbaties. De eventuele component van de anti-inflammatoire werking van 
macroliden moet onderzocht worden door de verandering van het inflammatoire profiel (inclusief 
cytokines) te meten in sputum en serum gedurende behandeling, in relatie tot de afname in 
exacerbaties. 
Studies naar de effecten van langdurige behandeling met non-antibiotische macroliden bij COPD 
patiënten met frequente exacerbaties zou ook een helder antwoord kunnen geven op de vraag of de 
exacerbatiereductie met name berust op de anti-inflammatoire werking. 
De ontwikkeling van macrolide resistentie tijdens onderhoudsbehandeling blijft een belangrijke 
reden tot zorg.  
Bij onderzoek naar deze vorm van therapie is het van belang om uitgebreide kweken te verrichten 
met bepaling van resistentie patronen van bacteriën in de nasopharynx en de darmen teneinde de 
eventuele ontwikkeling van resistentie te kunnen vaststellen. 
In het huidige onderzoek is de ontwikkeling van verschillende macrolide resistentie genen in 
pharyngeale flora onderzocht. Bij toekomstig onderzoek zou ook de ontwikkeling van deze genen in 
darmflora onderzocht moeten worden. 
Tenslotte is van belang om te onderzoeken of onderhoudsbehandeling met macroliden gevolgen 
heeft voor de samenstelling van microbiële flora in farynx en darm.  
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Hierbij zou gebruik gemaakt kunnen worden van nieuwe technieken zoals IS-PRO of metagenomische 
sequencing, waarbij bacteriën kunnen worden vastgesteld zonder kweek. Zodoende kunnen de 
(lange termijn) effecten van antibiotische therapie nog beter in kaart gebracht worden zodat een 
goede afweging mogelijk is van de baten en de nadelige effecten. 
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